[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$ffVqeFU13t4guASSGoGGcDhaGPPzE45mqCFRbKx0BbkI":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":86,"rows":93},"University Hospital, Strasbourg, France",[4],957,false,248,34,1066836,44,839,[14,17,20,23,26,28,31,33],{"name":15,"count":16},"Schizophrenia",18,{"name":18,"count":19},"COVID-19",16,{"name":21,"count":22},"Covid-19",12,{"name":24,"count":25},"Multiple Sclerosis",7,{"name":27,"count":25},"Breast Cancer",{"name":29,"count":30},"Rheumatoid Arthritis",6,{"name":32,"count":30},"Cystic Fibrosis",{"name":34,"count":30},"Palliative Care",[36,41,46,51,56,61,66,71,76,81],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT04164576","Study of the Pathogenicity and Humoral Immune Response Induced by BK Virus in Lung Transplant Recipients","2020-01","Transplant patients",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT06705829","Comparative Evaluation of the Performance of Different Thromboplastin Reagents on Prothrombin Time and Factorial Assays in Situations of Isolated Extrinsic Pathway Factor Deficiency or Liver Damage.","2024-12-14","Prothrombin",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT04461444","COhort for Bardet-Bield Syndrome and Alström Syndrome for Translational Research Monocentric Interventional Study","2025-02","Skin biopsy",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT04720339","Molecular Monitoring of cfDNA by ddPCR in Non-small Cell Lung Cancer Treated by Immunotherapy.","2025-05-27","Molecular monitoring by quantification of cell-free DNA",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT03849131","Patient-Reported AutoImmunity Secondary to Cancer immunothErapy","2025-06","Biological collection",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT06651372","The Interest of Systematic Screening for Dengue, Chikungunya, and Zika, in Malaria-negative Return Travelers","2025-08-01","The retrospective analyses planned for these samples consist of serological analysis and molecular analysis (RT-PCR ) according to the date of symptoms ons",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT03580785","Primary Failure of Eruption (PFE) : Highlighting of Clinical, Radiological and Genetic Diagnostic Criteria: Consequences on the Therapeutic Management","2025-10-12","genetic analysis",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT06887426","Cladribine Tablets as an Exit Therapy Strategy","2025-12","Cladribine",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT05092984","Evaluation of Spironolactone Efficacy in Patient with Rheumatoid Arthritis (RA)","2026-03","Spironolactone",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT06012097","Impact of Gel Aromatherapy on Pain for Patients With De Quervain Disease","2026-04-01","Diclofenac gel",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,119,137,159,185,203,230,248,277,302,328,346,371,398,416,436,461,486,504,531,549,574,600,626,644,673,691,716,741,759,786,807,832,852,874,901,930,954,981,1005,1028,1048,1074,1102,1122,1149,1175,1193,1220,1238,1263,1292,1310,1338,1356,1384,1402,1427,1445,1468,1492,1517,1543,1569,1587,1613,1631,1655,1673,1700,1718,1741,1780,1802,1840,1865,1890,1908,1934,1958,1976,1994,2018,2043,2067,2085,2112,2130,2156,2174,2192,2210,2228,2251,2277,2295,2320,2346,2364,2387,2413,2431,2455,2482,2500,2525,2551,2578,2596,2619,2645,2663,2689,2714,2739,2793,2843,2879,2907,2932,2958,2984,3010,3032,3057,3082,3103,3127,3151,3173,3197,3224,3242,3267,3285,3308,3326,3354,3381,3399,3417,3442,3467,3485,3510,3528,3553,3571,3595,3620,3642,3667,3694,3712,3730,3753,3781],{"intervention":85,"totalTrials":95,"cells":96},1,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":117},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[],{"trials":105,"activeCount":99},[],{"trials":107,"activeCount":95,"soonestReadout":84},[108],{"nctId":82,"briefTitle":83,"status":109,"phases":110,"primaryCompletion":84,"completion":84,"start":111,"enrollment":112,"conditions":113,"interventions":115},"RECRUITING",[91],"2024-06-04",70,[114],"De Quervain Disease",[85,116],"Aromatherapy gel",{"trials":118,"activeCount":99},[],{"intervention":116,"totalTrials":95,"cells":120},{"EARLY_PHASE1":121,"PHASE1":123,"PHASE2":125,"PHASE3":127,"PHASE4":129,"NA":135},{"trials":122,"activeCount":99},[],{"trials":124,"activeCount":99},[],{"trials":126,"activeCount":99},[],{"trials":128,"activeCount":99},[],{"trials":130,"activeCount":95,"soonestReadout":84},[131],{"nctId":82,"briefTitle":83,"status":109,"phases":132,"primaryCompletion":84,"completion":84,"start":111,"enrollment":112,"conditions":133,"interventions":134},[91],[114],[85,116],{"trials":136,"activeCount":99},[],{"intervention":60,"totalTrials":95,"cells":138},{"EARLY_PHASE1":139,"PHASE1":141,"PHASE2":143,"PHASE3":145,"PHASE4":147,"NA":157},{"trials":140,"activeCount":99},[],{"trials":142,"activeCount":99},[],{"trials":144,"activeCount":99},[],{"trials":146,"activeCount":99},[],{"trials":148,"activeCount":95,"soonestReadout":59},[149],{"nctId":57,"briefTitle":58,"status":150,"phases":151,"primaryCompletion":59,"completion":59,"start":152,"enrollment":153,"conditions":154,"interventions":156},"ACTIVE_NOT_RECRUITING",[91],"2019-11-29",905,[155],"Opportunistic Autoimmune Diseases",[60],{"trials":158,"activeCount":99},[],{"intervention":160,"totalTrials":95,"cells":161},"Methotrexate + targeted therapy administration",{"EARLY_PHASE1":162,"PHASE1":164,"PHASE2":166,"PHASE3":168,"PHASE4":170,"NA":183},{"trials":163,"activeCount":99},[],{"trials":165,"activeCount":99},[],{"trials":167,"activeCount":99},[],{"trials":169,"activeCount":99},[],{"trials":171,"activeCount":95,"soonestReadout":176},[172],{"nctId":173,"briefTitle":174,"status":109,"phases":175,"primaryCompletion":176,"completion":176,"start":177,"enrollment":178,"conditions":179,"interventions":181},"NCT02714634","Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide",[91],"2029-03","2016-03-30",286,[29,180],"Insufficient Response to Methotrexate or Leflunomide",[160,182],"methotrexate or leflunomide + sulfasalazine + hydroxychloroquine administration",{"trials":184,"activeCount":99},[],{"intervention":182,"totalTrials":95,"cells":186},{"EARLY_PHASE1":187,"PHASE1":189,"PHASE2":191,"PHASE3":193,"PHASE4":195,"NA":201},{"trials":188,"activeCount":99},[],{"trials":190,"activeCount":99},[],{"trials":192,"activeCount":99},[],{"trials":194,"activeCount":99},[],{"trials":196,"activeCount":95,"soonestReadout":176},[197],{"nctId":173,"briefTitle":174,"status":109,"phases":198,"primaryCompletion":176,"completion":176,"start":177,"enrollment":178,"conditions":199,"interventions":200},[91],[29,180],[160,182],{"trials":202,"activeCount":99},[],{"intervention":204,"totalTrials":95,"cells":205},"Rituximab 200mg\u002F6months",{"EARLY_PHASE1":206,"PHASE1":208,"PHASE2":210,"PHASE3":212,"PHASE4":214,"NA":228},{"trials":207,"activeCount":99},[],{"trials":209,"activeCount":99},[],{"trials":211,"activeCount":99},[],{"trials":213,"activeCount":99},[],{"trials":215,"activeCount":95,"soonestReadout":220},[216],{"nctId":217,"briefTitle":218,"status":109,"phases":219,"primaryCompletion":220,"completion":220,"start":221,"enrollment":222,"conditions":223,"interventions":226},"NCT06906549","Evaluation of 200 mg of Rituximab Every 6 Months as Maintenance Treatment of Rituximab-treated Patients With Rheumatoid Arthritis",[91],"2026-07","2025-07-11",260,[224,225],"Rheumatoid Arthritis (RA)","Rituximab (RTx)",[204,227],"Rituximab 1g\u002F6months",{"trials":229,"activeCount":99},[],{"intervention":227,"totalTrials":95,"cells":231},{"EARLY_PHASE1":232,"PHASE1":234,"PHASE2":236,"PHASE3":238,"PHASE4":240,"NA":246},{"trials":233,"activeCount":99},[],{"trials":235,"activeCount":99},[],{"trials":237,"activeCount":99},[],{"trials":239,"activeCount":99},[],{"trials":241,"activeCount":95,"soonestReadout":220},[242],{"nctId":217,"briefTitle":218,"status":109,"phases":243,"primaryCompletion":220,"completion":220,"start":221,"enrollment":222,"conditions":244,"interventions":245},[91],[224,225],[204,227],{"trials":247,"activeCount":99},[],{"intervention":249,"totalTrials":95,"cells":250},"Hydrocortisone Hemisuccinate: 200 mg per day.",{"EARLY_PHASE1":251,"PHASE1":253,"PHASE2":255,"PHASE3":257,"PHASE4":259,"NA":275},{"trials":252,"activeCount":99},[],{"trials":254,"activeCount":99},[],{"trials":256,"activeCount":99},[],{"trials":258,"activeCount":99},[],{"trials":260,"activeCount":95,"soonestReadout":266},[261],{"nctId":262,"briefTitle":263,"status":264,"phases":265,"primaryCompletion":266,"completion":266,"start":267,"enrollment":268,"conditions":269,"interventions":274},"NCT06881927","Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and\u002For Acute Respiratory Failure","NOT_YET_RECRUITING",[91],"2029-06-01","2026-02-01",212,[270,271,272,273],"Sepsis and Septic Shock","Acute Respiratory Failure","Kidney Transplant Recipients","Immunosuppressive Agents",[249],{"trials":276,"activeCount":99},[],{"intervention":278,"totalTrials":95,"cells":279},"Prothrombin time",{"EARLY_PHASE1":280,"PHASE1":282,"PHASE2":284,"PHASE3":286,"PHASE4":288,"NA":300},{"trials":281,"activeCount":99},[],{"trials":283,"activeCount":99},[],{"trials":285,"activeCount":99},[],{"trials":287,"activeCount":99},[],{"trials":289,"activeCount":95,"soonestReadout":294},[290],{"nctId":291,"briefTitle":292,"status":264,"phases":293,"primaryCompletion":294,"completion":294,"start":295,"enrollment":296,"conditions":297,"interventions":299},"NCT06974396","Comparative Evaluation of the Performance of Different Thromboplastin Reagents on Prothrombin Time in Situations of Isolated Extrinsic Pathway Factor Deficiency or Liver Damage",[91],"2026-12-01","2025-09-01",20,[298],"Hemorrhagic Disorders",[278],{"trials":301,"activeCount":99},[],{"intervention":303,"totalTrials":95,"cells":304},"Isotretinoin",{"EARLY_PHASE1":305,"PHASE1":307,"PHASE2":309,"PHASE3":311,"PHASE4":313,"NA":326},{"trials":306,"activeCount":99},[],{"trials":308,"activeCount":99},[],{"trials":310,"activeCount":99},[],{"trials":312,"activeCount":99},[],{"trials":314,"activeCount":95,"soonestReadout":319},[315],{"nctId":316,"briefTitle":317,"status":264,"phases":318,"primaryCompletion":319,"completion":319,"start":320,"enrollment":321,"conditions":322,"interventions":324},"NCT06698263","13-cis Retinoic Acid (Isotretinoin) and Sperm Production",[91],"2027-12-01","2025-03-01",100,[323],"Men with Infertility",[303,325],"Control group",{"trials":327,"activeCount":99},[],{"intervention":325,"totalTrials":95,"cells":329},{"EARLY_PHASE1":330,"PHASE1":332,"PHASE2":334,"PHASE3":336,"PHASE4":338,"NA":344},{"trials":331,"activeCount":99},[],{"trials":333,"activeCount":99},[],{"trials":335,"activeCount":99},[],{"trials":337,"activeCount":99},[],{"trials":339,"activeCount":95,"soonestReadout":319},[340],{"nctId":316,"briefTitle":317,"status":264,"phases":341,"primaryCompletion":319,"completion":319,"start":320,"enrollment":321,"conditions":342,"interventions":343},[91],[323],[303,325],{"trials":345,"activeCount":99},[],{"intervention":347,"totalTrials":95,"cells":348},"Rituximab",{"EARLY_PHASE1":349,"PHASE1":351,"PHASE2":353,"PHASE3":355,"PHASE4":357,"NA":369},{"trials":350,"activeCount":99},[],{"trials":352,"activeCount":99},[],{"trials":354,"activeCount":99},[],{"trials":356,"activeCount":99},[],{"trials":358,"activeCount":95,"soonestReadout":363},[359],{"nctId":360,"briefTitle":361,"status":109,"phases":362,"primaryCompletion":363,"completion":363,"start":364,"enrollment":365,"conditions":366,"interventions":368},"NCT04989491","Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg\u002Fm2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft",[91],"2029-12-01","2021-12-01",120,[367],"Epstein-Barr Virus Infections",[347],{"trials":370,"activeCount":99},[],{"intervention":372,"totalTrials":95,"cells":373},"Dornase Alfa Inhalant Solution [Pulmozyme]",{"EARLY_PHASE1":374,"PHASE1":376,"PHASE2":378,"PHASE3":380,"PHASE4":394,"NA":396},{"trials":375,"activeCount":99},[],{"trials":377,"activeCount":99},[],{"trials":379,"activeCount":99},[],{"trials":381,"activeCount":95,"soonestReadout":386},[382],{"nctId":383,"briefTitle":384,"status":109,"phases":385,"primaryCompletion":386,"completion":319,"start":387,"enrollment":388,"conditions":389,"interventions":392},"NCT03368092","Inhaled Dornase Alpha to Reduce Respiratory Failure After Severe Trauma",[90],"2027-09-01","2019-03-04",500,[390,391],"Multiple Trauma","Respiratory Distress Syndrome, Adult",[372,393],"Placebos",{"trials":395,"activeCount":99},[],{"trials":397,"activeCount":99},[],{"intervention":393,"totalTrials":95,"cells":399},{"EARLY_PHASE1":400,"PHASE1":402,"PHASE2":404,"PHASE3":406,"PHASE4":412,"NA":414},{"trials":401,"activeCount":99},[],{"trials":403,"activeCount":99},[],{"trials":405,"activeCount":99},[],{"trials":407,"activeCount":95,"soonestReadout":386},[408],{"nctId":383,"briefTitle":384,"status":109,"phases":409,"primaryCompletion":386,"completion":319,"start":387,"enrollment":388,"conditions":410,"interventions":411},[90],[390,391],[372,393],{"trials":413,"activeCount":99},[],{"trials":415,"activeCount":99},[],{"intervention":80,"totalTrials":95,"cells":417},{"EARLY_PHASE1":418,"PHASE1":420,"PHASE2":422,"PHASE3":424,"PHASE4":432,"NA":434},{"trials":419,"activeCount":99},[],{"trials":421,"activeCount":99},[],{"trials":423,"activeCount":99},[],{"trials":425,"activeCount":95,"soonestReadout":79},[426],{"nctId":77,"briefTitle":78,"status":109,"phases":427,"primaryCompletion":79,"completion":79,"start":428,"enrollment":429,"conditions":430,"interventions":431},[90],"2022-06-22",154,[29],[80],{"trials":433,"activeCount":99},[],{"trials":435,"activeCount":99},[],{"intervention":437,"totalTrials":95,"cells":438},"Dapaglifozin",{"EARLY_PHASE1":439,"PHASE1":441,"PHASE2":443,"PHASE3":445,"PHASE4":457,"NA":459},{"trials":440,"activeCount":99},[],{"trials":442,"activeCount":99},[],{"trials":444,"activeCount":99},[],{"trials":446,"activeCount":95,"soonestReadout":451},[447],{"nctId":448,"briefTitle":449,"status":264,"phases":450,"primaryCompletion":451,"completion":452,"start":220,"enrollment":453,"conditions":454,"interventions":456},"NCT07488689","Assessing the Efficacy of Dapagliflozin as a Vasculoprotective Treatment in Septic Shock Patients With Microcirculatory Dysfunction",[90],"2029-08","2030-07",568,[455],"Septic Shock",[437],{"trials":458,"activeCount":99},[],{"trials":460,"activeCount":99},[],{"intervention":462,"totalTrials":95,"cells":463},"no NSAID",{"EARLY_PHASE1":464,"PHASE1":466,"PHASE2":468,"PHASE3":470,"PHASE4":482,"NA":484},{"trials":465,"activeCount":99},[],{"trials":467,"activeCount":99},[],{"trials":469,"activeCount":99},[],{"trials":471,"activeCount":95,"soonestReadout":476},[472],{"nctId":473,"briefTitle":474,"status":264,"phases":475,"primaryCompletion":476,"completion":476,"start":84,"enrollment":477,"conditions":478,"interventions":480},"NCT07108582","Reducing Chronic Pain After Lung Surgery: A Trial of Limiting NSAIDs During Recovery",[90],"2028-07-01",270,[479],"Chronic Post-operative Pain",[462,481],"protocol for administering NSAIDs already used in routine care",{"trials":483,"activeCount":99},[],{"trials":485,"activeCount":99},[],{"intervention":481,"totalTrials":95,"cells":487},{"EARLY_PHASE1":488,"PHASE1":490,"PHASE2":492,"PHASE3":494,"PHASE4":500,"NA":502},{"trials":489,"activeCount":99},[],{"trials":491,"activeCount":99},[],{"trials":493,"activeCount":99},[],{"trials":495,"activeCount":95,"soonestReadout":476},[496],{"nctId":473,"briefTitle":474,"status":264,"phases":497,"primaryCompletion":476,"completion":476,"start":84,"enrollment":477,"conditions":498,"interventions":499},[90],[479],[462,481],{"trials":501,"activeCount":99},[],{"trials":503,"activeCount":99},[],{"intervention":505,"totalTrials":95,"cells":506},"treatment withdrawal",{"EARLY_PHASE1":507,"PHASE1":509,"PHASE2":511,"PHASE3":513,"PHASE4":527,"NA":529},{"trials":508,"activeCount":99},[],{"trials":510,"activeCount":99},[],{"trials":512,"activeCount":99},[],{"trials":514,"activeCount":95,"soonestReadout":519},[515],{"nctId":516,"briefTitle":517,"status":264,"phases":518,"primaryCompletion":519,"completion":520,"start":521,"enrollment":522,"conditions":523,"interventions":525},"NCT06663189","Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)",[90],"2027-01","2029-06","2025-01",200,[524],"Relapsing-remitting Multiple Sclerosis (RRMS)",[505,526],"Usual DMT continuation",{"trials":528,"activeCount":99},[],{"trials":530,"activeCount":99},[],{"intervention":526,"totalTrials":95,"cells":532},{"EARLY_PHASE1":533,"PHASE1":535,"PHASE2":537,"PHASE3":539,"PHASE4":545,"NA":547},{"trials":534,"activeCount":99},[],{"trials":536,"activeCount":99},[],{"trials":538,"activeCount":99},[],{"trials":540,"activeCount":95,"soonestReadout":519},[541],{"nctId":516,"briefTitle":517,"status":264,"phases":542,"primaryCompletion":519,"completion":520,"start":521,"enrollment":522,"conditions":543,"interventions":544},[90],[524],[505,526],{"trials":546,"activeCount":99},[],{"trials":548,"activeCount":99},[],{"intervention":550,"totalTrials":95,"cells":551},"pediatric, prolonged released melatonin",{"EARLY_PHASE1":552,"PHASE1":554,"PHASE2":556,"PHASE3":558,"PHASE4":570,"NA":572},{"trials":553,"activeCount":99},[],{"trials":555,"activeCount":99},[],{"trials":557,"activeCount":99},[],{"trials":559,"activeCount":95,"soonestReadout":564},[560],{"nctId":561,"briefTitle":562,"status":264,"phases":563,"primaryCompletion":564,"completion":266,"start":565,"enrollment":365,"conditions":566,"interventions":569},"NCT07418554","Sleep Disturbances in Children and Adolescents With Post-traumatic Stress Disorder (PTSD): a Randomized Double-blind Placebo-controlled Trial to Investigate the Efficacy of Pediatric Prolonged-release Melatonin",[90],"2029-05-01","2027-01-01",[567,568],"Post-traumatic Stress Disorder (PTSD)","Current Significant Sleep Disturbances",[550],{"trials":571,"activeCount":99},[],{"trials":573,"activeCount":99},[],{"intervention":575,"totalTrials":95,"cells":576},"Methylphenidate immediate release 25mg",{"EARLY_PHASE1":577,"PHASE1":579,"PHASE2":581,"PHASE3":583,"PHASE4":596,"NA":598},{"trials":578,"activeCount":99},[],{"trials":580,"activeCount":99},[],{"trials":582,"activeCount":99},[],{"trials":584,"activeCount":95,"soonestReadout":589},[585],{"nctId":586,"briefTitle":587,"status":109,"phases":588,"primaryCompletion":589,"completion":589,"start":590,"enrollment":591,"conditions":592,"interventions":595},"NCT05832489","EEG-MRI Imaging of Methylphenidate Effects in Adult ADHD and Attentional Symptoms in Mood Disorders",[90],"2027-05","2024-02-26",80,[593,594],"Adult ADHD","Adult-onset ADHD With Mood Disorder",[575],{"trials":597,"activeCount":99},[],{"trials":599,"activeCount":99},[],{"intervention":601,"totalTrials":95,"cells":602},"- Melatonin - Active light ttherapy",{"EARLY_PHASE1":603,"PHASE1":605,"PHASE2":607,"PHASE3":620,"PHASE4":622,"NA":624},{"trials":604,"activeCount":99},[],{"trials":606,"activeCount":99},[],{"trials":608,"activeCount":95,"soonestReadout":613},[609],{"nctId":610,"briefTitle":611,"status":109,"phases":612,"primaryCompletion":613,"completion":613,"start":614,"enrollment":615,"conditions":616,"interventions":618},"NCT06252571","a Chronobiological Treatment Combining Evening Melatonin and Morning Light Therapy in Idiopathic Hypersomnia: a Prospective, Double Bind, Randomized, Placebo-controlled -Trial",[89],"2027-09-07","2024-09-07",72,[617],"Idiopathic Hypersomnia",[601,619],"- Placebo drug - Placebo light therapy",{"trials":621,"activeCount":99},[],{"trials":623,"activeCount":99},[],{"trials":625,"activeCount":99},[],{"intervention":619,"totalTrials":95,"cells":627},{"EARLY_PHASE1":628,"PHASE1":630,"PHASE2":632,"PHASE3":638,"PHASE4":640,"NA":642},{"trials":629,"activeCount":99},[],{"trials":631,"activeCount":99},[],{"trials":633,"activeCount":95,"soonestReadout":613},[634],{"nctId":610,"briefTitle":611,"status":109,"phases":635,"primaryCompletion":613,"completion":613,"start":614,"enrollment":615,"conditions":636,"interventions":637},[89],[617],[601,619],{"trials":639,"activeCount":99},[],{"trials":641,"activeCount":99},[],{"trials":643,"activeCount":99},[],{"intervention":645,"totalTrials":95,"cells":646},"Trametinib",{"EARLY_PHASE1":647,"PHASE1":649,"PHASE2":651,"PHASE3":667,"PHASE4":669,"NA":671},{"trials":648,"activeCount":99},[],{"trials":650,"activeCount":99},[],{"trials":652,"activeCount":95,"soonestReadout":657},[653],{"nctId":654,"briefTitle":655,"status":109,"phases":656,"primaryCompletion":657,"completion":658,"start":659,"enrollment":660,"conditions":661,"interventions":665},"NCT05180825","Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy",[89],"2031-11-01","2031-12-01","2022-05-05",134,[662,663,664],"Grade 1 Glioma","Mixed Glio-neuronal Tumors","Pleomorphic Xanthoastrocytoma",[645,666],"Vinblastine",{"trials":668,"activeCount":99},[],{"trials":670,"activeCount":99},[],{"trials":672,"activeCount":99},[],{"intervention":666,"totalTrials":95,"cells":674},{"EARLY_PHASE1":675,"PHASE1":677,"PHASE2":679,"PHASE3":685,"PHASE4":687,"NA":689},{"trials":676,"activeCount":99},[],{"trials":678,"activeCount":99},[],{"trials":680,"activeCount":95,"soonestReadout":657},[681],{"nctId":654,"briefTitle":655,"status":109,"phases":682,"primaryCompletion":657,"completion":658,"start":659,"enrollment":660,"conditions":683,"interventions":684},[89],[662,663,664],[645,666],{"trials":686,"activeCount":99},[],{"trials":688,"activeCount":99},[],{"trials":690,"activeCount":99},[],{"intervention":692,"totalTrials":95,"cells":693},"Nebido® Testosterone Undecanoate 1000 Mg\u002F4 mL Solution for",{"EARLY_PHASE1":694,"PHASE1":696,"PHASE2":698,"PHASE3":710,"PHASE4":712,"NA":714},{"trials":695,"activeCount":99},[],{"trials":697,"activeCount":99},[],{"trials":699,"activeCount":95,"soonestReadout":704},[700],{"nctId":701,"briefTitle":702,"status":109,"phases":703,"primaryCompletion":704,"completion":704,"start":705,"enrollment":706,"conditions":707,"interventions":709},"NCT03910738","TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis",[89],"2027-12","2019-10-29",40,[708],"Multiple Sclerosis, Relapsing-Remitting",[692],{"trials":711,"activeCount":99},[],{"trials":713,"activeCount":99},[],{"trials":715,"activeCount":99},[],{"intervention":717,"totalTrials":95,"cells":718},"• Sivelestat intravenous",{"EARLY_PHASE1":719,"PHASE1":721,"PHASE2":723,"PHASE3":735,"PHASE4":737,"NA":739},{"trials":720,"activeCount":99},[],{"trials":722,"activeCount":99},[],{"trials":724,"activeCount":95,"soonestReadout":729},[725],{"nctId":726,"briefTitle":727,"status":264,"phases":728,"primaryCompletion":729,"completion":729,"start":730,"enrollment":365,"conditions":731,"interventions":733},"NCT07214103","Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients With Septic Coagulopathy",[89],"2032-12-31","2026-03-01",[455,732],"Coagulopathy",[717,734],"NaCl intravenous",{"trials":736,"activeCount":99},[],{"trials":738,"activeCount":99},[],{"trials":740,"activeCount":99},[],{"intervention":734,"totalTrials":95,"cells":742},{"EARLY_PHASE1":743,"PHASE1":745,"PHASE2":747,"PHASE3":753,"PHASE4":755,"NA":757},{"trials":744,"activeCount":99},[],{"trials":746,"activeCount":99},[],{"trials":748,"activeCount":95,"soonestReadout":729},[749],{"nctId":726,"briefTitle":727,"status":264,"phases":750,"primaryCompletion":729,"completion":729,"start":730,"enrollment":365,"conditions":751,"interventions":752},[89],[455,732],[717,734],{"trials":754,"activeCount":99},[],{"trials":756,"activeCount":99},[],{"trials":758,"activeCount":99},[],{"intervention":760,"totalTrials":95,"cells":761},"Use of antipsychotic treatment with marketing authorization at doses lower than those recommended: - Olanzapine - Zuclopenthixol - Risperidone - Pipotiazine palmitate \u002F Pipotiazine - Quetiapine - Flup",{"EARLY_PHASE1":762,"PHASE1":764,"PHASE2":766,"PHASE3":780,"PHASE4":782,"NA":784},{"trials":763,"activeCount":99},[],{"trials":765,"activeCount":99},[],{"trials":767,"activeCount":95,"soonestReadout":772},[768],{"nctId":769,"briefTitle":770,"status":264,"phases":771,"primaryCompletion":772,"completion":772,"start":773,"enrollment":774,"conditions":775,"interventions":779},"NCT07152184","Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach",[89],"2032-02-01","2026-10-01",288,[776,777,778],"Patient With Schizophrenia Spectrum Disorder","NLM Classification WM 203, Psychology:Schizophrenic Psychology","Schizophrenia Spectrum and Other Psychotic Disorders",[760],{"trials":781,"activeCount":99},[],{"trials":783,"activeCount":99},[],{"trials":785,"activeCount":99},[],{"intervention":75,"totalTrials":95,"cells":787},{"EARLY_PHASE1":788,"PHASE1":790,"PHASE2":792,"PHASE3":794,"PHASE4":796,"NA":798},{"trials":789,"activeCount":99},[],{"trials":791,"activeCount":99},[],{"trials":793,"activeCount":99},[],{"trials":795,"activeCount":99},[],{"trials":797,"activeCount":99},[],{"trials":799,"activeCount":95,"soonestReadout":74},[800],{"nctId":72,"briefTitle":73,"status":264,"phases":801,"primaryCompletion":74,"completion":74,"start":59,"enrollment":802,"conditions":803,"interventions":806},[],450,[24,804,805],"Relapsing Remitting Multiple Sclerosis","Secondary Progressive Multiple Sclerosis",[75],{"intervention":808,"totalTrials":95,"cells":809},"Genetic diagnosis",{"EARLY_PHASE1":810,"PHASE1":812,"PHASE2":814,"PHASE3":816,"PHASE4":818,"NA":820},{"trials":811,"activeCount":99},[],{"trials":813,"activeCount":99},[],{"trials":815,"activeCount":99},[],{"trials":817,"activeCount":99},[],{"trials":819,"activeCount":99},[],{"trials":821,"activeCount":95,"soonestReadout":826},[822],{"nctId":823,"briefTitle":824,"status":109,"phases":825,"primaryCompletion":826,"completion":826,"start":827,"enrollment":828,"conditions":829,"interventions":831},"NCT04261127","Validation of the RADIAL Algorithm for Diagnosis of Autosomal Recessive Cerebellar Ataxia",[92],"2029-09","2021-09-20",400,[830],"Autosomal Recessive Cerebellar Ataxia",[808],{"intervention":45,"totalTrials":95,"cells":833},{"EARLY_PHASE1":834,"PHASE1":836,"PHASE2":838,"PHASE3":840,"PHASE4":842,"NA":844},{"trials":835,"activeCount":99},[],{"trials":837,"activeCount":99},[],{"trials":839,"activeCount":99},[],{"trials":841,"activeCount":99},[],{"trials":843,"activeCount":99},[],{"trials":845,"activeCount":95,"soonestReadout":44},[846],{"nctId":42,"briefTitle":43,"status":109,"phases":847,"primaryCompletion":44,"completion":74,"start":44,"enrollment":321,"conditions":848,"interventions":851},[],[298,849,850],"Extrinsic Pathway Factor Deficiency","Hepatocellular Insufficiency With Coagulopathy",[45],{"intervention":40,"totalTrials":95,"cells":853},{"EARLY_PHASE1":854,"PHASE1":856,"PHASE2":858,"PHASE3":860,"PHASE4":862,"NA":864},{"trials":855,"activeCount":99},[],{"trials":857,"activeCount":99},[],{"trials":859,"activeCount":99},[],{"trials":861,"activeCount":99},[],{"trials":863,"activeCount":99},[],{"trials":865,"activeCount":95,"soonestReadout":39},[866],{"nctId":37,"briefTitle":38,"status":264,"phases":867,"primaryCompletion":39,"completion":868,"start":39,"enrollment":365,"conditions":869,"interventions":873},[],"2027-06",[870,871,872],"Renal-urinary Impairment","Graft Rejection","Infection Episodes",[40],{"intervention":875,"totalTrials":95,"cells":876},"An additional volume of blood will be drawn as part of routine follow-up care",{"EARLY_PHASE1":877,"PHASE1":879,"PHASE2":881,"PHASE3":883,"PHASE4":885,"NA":887},{"trials":878,"activeCount":99},[],{"trials":880,"activeCount":99},[],{"trials":882,"activeCount":99},[],{"trials":884,"activeCount":99},[],{"trials":886,"activeCount":99},[],{"trials":888,"activeCount":95,"soonestReadout":893},[889],{"nctId":890,"briefTitle":891,"status":264,"phases":892,"primaryCompletion":893,"completion":893,"start":894,"enrollment":895,"conditions":896,"interventions":900},"NCT07234630","Role of Fibrinolytic Activity in Neoplastic Pathologies Complicated by Coagulopathy",[],"2028-02","2026-01",150,[897,898,899],"Hematologic Neoplasms","Solid Tumor Metastatic Cancer Advanced Cancer","Disseminated Intravascular Coagulation",[875],{"intervention":902,"totalTrials":95,"cells":903},"Blood draw, Urine draw",{"EARLY_PHASE1":904,"PHASE1":906,"PHASE2":908,"PHASE3":910,"PHASE4":912,"NA":914},{"trials":905,"activeCount":99},[],{"trials":907,"activeCount":99},[],{"trials":909,"activeCount":99},[],{"trials":911,"activeCount":99},[],{"trials":913,"activeCount":99},[],{"trials":915,"activeCount":95,"soonestReadout":920},[916],{"nctId":917,"briefTitle":918,"status":264,"phases":919,"primaryCompletion":920,"completion":921,"start":922,"enrollment":923,"conditions":924,"interventions":929},"NCT05890430","Study of Alloimmune Response in Humoral Rejection After Kidney Transplantation",[],"2033-06","2033-07","2023-06",570,[925,926,927,928],"Kidney Transplantation","Kidney Allograft Biopsy","Humoral Rejection","Microvascular Inflammation",[902],{"intervention":931,"totalTrials":95,"cells":932},"Chemotherapy drug",{"EARLY_PHASE1":933,"PHASE1":935,"PHASE2":937,"PHASE3":939,"PHASE4":941,"NA":943},{"trials":934,"activeCount":99},[],{"trials":936,"activeCount":99},[],{"trials":938,"activeCount":99},[],{"trials":940,"activeCount":99},[],{"trials":942,"activeCount":99},[],{"trials":944,"activeCount":95,"soonestReadout":949},[945],{"nctId":946,"briefTitle":947,"status":109,"phases":948,"primaryCompletion":949,"completion":520,"start":950,"enrollment":895,"conditions":951,"interventions":953},"NCT06081400","Cryoablation Versus Medical Therapy in Desmoid Tumors Progressing After Watchful Waiting",[92],"2027-03","2024-03-04",[952],"Desmoid Tumor",[931],{"intervention":955,"totalTrials":95,"cells":956},"Biological samples will be done to evaluate the endothelial and leukocyte senescence.",{"EARLY_PHASE1":957,"PHASE1":959,"PHASE2":961,"PHASE3":963,"PHASE4":965,"NA":967},{"trials":958,"activeCount":99},[],{"trials":960,"activeCount":99},[],{"trials":962,"activeCount":99},[],{"trials":964,"activeCount":99},[],{"trials":966,"activeCount":99},[],{"trials":968,"activeCount":95,"soonestReadout":893},[969],{"nctId":970,"briefTitle":971,"status":109,"phases":972,"primaryCompletion":893,"completion":973,"start":974,"enrollment":975,"conditions":976,"interventions":980},"NCT03559569","Impact of Endothelial and Leukocyte Senescence in Circulatory Shock States",[],"2028-03","2019-01-07",520,[977,978,979],"Shock","Cardiovascular Diseases","Infection",[955],{"intervention":55,"totalTrials":95,"cells":982},{"EARLY_PHASE1":983,"PHASE1":985,"PHASE2":987,"PHASE3":989,"PHASE4":991,"NA":993},{"trials":984,"activeCount":99},[],{"trials":986,"activeCount":99},[],{"trials":988,"activeCount":99},[],{"trials":990,"activeCount":99},[],{"trials":992,"activeCount":99},[],{"trials":994,"activeCount":95,"soonestReadout":54},[995],{"nctId":52,"briefTitle":53,"status":109,"phases":996,"primaryCompletion":54,"completion":997,"start":998,"enrollment":999,"conditions":1000,"interventions":1004},[92],"2027-10-27","2021-05-27",250,[1001,1002,1003],"NSCLC","IMMUNOTHERAPY","QUANTIFICATION OF CELL-FREE DNA",[55],{"intervention":50,"totalTrials":95,"cells":1006},{"EARLY_PHASE1":1007,"PHASE1":1009,"PHASE2":1011,"PHASE3":1013,"PHASE4":1015,"NA":1017},{"trials":1008,"activeCount":99},[],{"trials":1010,"activeCount":99},[],{"trials":1012,"activeCount":99},[],{"trials":1014,"activeCount":99},[],{"trials":1016,"activeCount":99},[],{"trials":1018,"activeCount":95,"soonestReadout":49},[1019],{"nctId":47,"briefTitle":48,"status":109,"phases":1020,"primaryCompletion":49,"completion":1021,"start":1022,"enrollment":1023,"conditions":1024,"interventions":1027},[92],"2035-02","2020-06-16",350,[1025,1026],"Bardet-Biedl Syndrome","Alström Syndrome",[50],{"intervention":65,"totalTrials":95,"cells":1029},{"EARLY_PHASE1":1030,"PHASE1":1032,"PHASE2":1034,"PHASE3":1036,"PHASE4":1038,"NA":1040},{"trials":1031,"activeCount":99},[],{"trials":1033,"activeCount":99},[],{"trials":1035,"activeCount":99},[],{"trials":1037,"activeCount":99},[],{"trials":1039,"activeCount":99},[],{"trials":1041,"activeCount":95,"soonestReadout":64},[1042],{"nctId":62,"briefTitle":63,"status":150,"phases":1043,"primaryCompletion":64,"completion":1044,"start":64,"enrollment":522,"conditions":1045,"interventions":1047},[],"2026-08",[1046],"Arbovirus Infections",[65],{"intervention":1049,"totalTrials":95,"cells":1050},"cfDNA analysis",{"EARLY_PHASE1":1051,"PHASE1":1053,"PHASE2":1055,"PHASE3":1057,"PHASE4":1059,"NA":1061},{"trials":1052,"activeCount":99},[],{"trials":1054,"activeCount":99},[],{"trials":1056,"activeCount":99},[],{"trials":1058,"activeCount":99},[],{"trials":1060,"activeCount":99},[],{"trials":1062,"activeCount":95,"soonestReadout":1067},[1063],{"nctId":1064,"briefTitle":1065,"status":109,"phases":1066,"primaryCompletion":1067,"completion":1068,"start":1069,"enrollment":1070,"conditions":1071,"interventions":1073},"NCT06202846","Identification of Y Chromosome From Free Circulating DNA in Patients With Turner Syndrome",[92],"2028-06","2028-10","2024-02-28",50,[1072],"Turner Syndrome",[1049],{"intervention":1075,"totalTrials":95,"cells":1076},"blood draw",{"EARLY_PHASE1":1077,"PHASE1":1079,"PHASE2":1081,"PHASE3":1083,"PHASE4":1085,"NA":1087},{"trials":1078,"activeCount":99},[],{"trials":1080,"activeCount":99},[],{"trials":1082,"activeCount":99},[],{"trials":1084,"activeCount":99},[],{"trials":1086,"activeCount":99},[],{"trials":1088,"activeCount":95,"soonestReadout":1093},[1089],{"nctId":1090,"briefTitle":1091,"status":264,"phases":1092,"primaryCompletion":1093,"completion":1093,"start":1094,"enrollment":522,"conditions":1095,"interventions":1101},"NCT07251179","Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies",[],"2031-12-31","2026-01-01",[1096,1097,1098,1099,1100],"Systemic Lupus Erythematosus","Systemic Scleroderma","ANCA-associated Vasculitis","Antiphospholipid Syndrome","Primary Immunodeficiencies",[1075],{"intervention":70,"totalTrials":95,"cells":1103},{"EARLY_PHASE1":1104,"PHASE1":1106,"PHASE2":1108,"PHASE3":1110,"PHASE4":1112,"NA":1114},{"trials":1105,"activeCount":99},[],{"trials":1107,"activeCount":99},[],{"trials":1109,"activeCount":99},[],{"trials":1111,"activeCount":99},[],{"trials":1113,"activeCount":99},[],{"trials":1115,"activeCount":95,"soonestReadout":69},[1116],{"nctId":67,"briefTitle":68,"status":109,"phases":1117,"primaryCompletion":69,"completion":69,"start":1118,"enrollment":1070,"conditions":1119,"interventions":1121},[92],"2018-10-22",[1120],"Primary Failure of Eruption",[70],{"intervention":1123,"totalTrials":95,"cells":1124},"Enoxaparin",{"EARLY_PHASE1":1125,"PHASE1":1127,"PHASE2":1129,"PHASE3":1131,"PHASE4":1133,"NA":1147},{"trials":1126,"activeCount":99},[],{"trials":1128,"activeCount":99},[],{"trials":1130,"activeCount":99},[],{"trials":1132,"activeCount":99},[],{"trials":1134,"activeCount":99},[1135],{"nctId":1136,"briefTitle":1137,"status":1138,"phases":1139,"primaryCompletion":1140,"completion":1141,"start":1142,"enrollment":1143,"conditions":1144,"interventions":1146},"NCT00444652","Thromboprophylaxis and Bariatric Surgery","UNKNOWN",[91],"2012-11","2012-12","2006-11",300,[1145],"Thromboembolism",[1123],{"trials":1148,"activeCount":99},[],{"intervention":1150,"totalTrials":95,"cells":1151},"Vildagliptin",{"EARLY_PHASE1":1152,"PHASE1":1154,"PHASE2":1156,"PHASE3":1158,"PHASE4":1160,"NA":1173},{"trials":1153,"activeCount":99},[],{"trials":1155,"activeCount":99},[],{"trials":1157,"activeCount":99},[],{"trials":1159,"activeCount":99},[],{"trials":1161,"activeCount":99},[1162],{"nctId":1163,"briefTitle":1164,"status":1165,"phases":1166,"primaryCompletion":1167,"completion":1167,"start":1168,"enrollment":112,"conditions":1169,"interventions":1171},"NCT02176681","A Prospective, Multicenter, Randomized, Open-label Study of 12 Week Duration to Evaluate the Effect of VILDagliptin Added to Insulin on Glycaemic Control in haemoDIALyzed Patients With Type 2 Diabetes: Probe Analysis of CGM","COMPLETED",[91],"2017-10","2014-06",[1170],"Haemodialyzed, Type 2 Diabetes",[1150,1172],"Insulin",{"trials":1174,"activeCount":99},[],{"intervention":1172,"totalTrials":95,"cells":1176},{"EARLY_PHASE1":1177,"PHASE1":1179,"PHASE2":1181,"PHASE3":1183,"PHASE4":1185,"NA":1191},{"trials":1178,"activeCount":99},[],{"trials":1180,"activeCount":99},[],{"trials":1182,"activeCount":99},[],{"trials":1184,"activeCount":99},[],{"trials":1186,"activeCount":99},[1187],{"nctId":1163,"briefTitle":1164,"status":1165,"phases":1188,"primaryCompletion":1167,"completion":1167,"start":1168,"enrollment":112,"conditions":1189,"interventions":1190},[91],[1170],[1150,1172],{"trials":1192,"activeCount":99},[],{"intervention":1194,"totalTrials":95,"cells":1195},"ropivacaine 0.75% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL",{"EARLY_PHASE1":1196,"PHASE1":1198,"PHASE2":1200,"PHASE3":1202,"PHASE4":1204,"NA":1218},{"trials":1197,"activeCount":99},[],{"trials":1199,"activeCount":99},[],{"trials":1201,"activeCount":99},[],{"trials":1203,"activeCount":99},[],{"trials":1205,"activeCount":99},[1206],{"nctId":1207,"briefTitle":1208,"status":1165,"phases":1209,"primaryCompletion":1210,"completion":1211,"start":1210,"enrollment":1212,"conditions":1213,"interventions":1216},"NCT01698203","Continuous Wound Catheter Analgesia Associated With Intravenous Morphine PCA After Thoracotomy",[91],"2012-10-14","2018-10-11",92,[1214,1215],"Pain","Thoracotomy",[1194,1217],"ropivacaine 0.2% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL",{"trials":1219,"activeCount":99},[],{"intervention":1217,"totalTrials":95,"cells":1221},{"EARLY_PHASE1":1222,"PHASE1":1224,"PHASE2":1226,"PHASE3":1228,"PHASE4":1230,"NA":1236},{"trials":1223,"activeCount":99},[],{"trials":1225,"activeCount":99},[],{"trials":1227,"activeCount":99},[],{"trials":1229,"activeCount":99},[],{"trials":1231,"activeCount":99},[1232],{"nctId":1207,"briefTitle":1208,"status":1165,"phases":1233,"primaryCompletion":1210,"completion":1211,"start":1210,"enrollment":1212,"conditions":1234,"interventions":1235},[91],[1214,1215],[1194,1217],{"trials":1237,"activeCount":99},[],{"intervention":1239,"totalTrials":95,"cells":1240},"everolimus",{"EARLY_PHASE1":1241,"PHASE1":1243,"PHASE2":1245,"PHASE3":1247,"PHASE4":1249,"NA":1261},{"trials":1242,"activeCount":99},[],{"trials":1244,"activeCount":99},[],{"trials":1246,"activeCount":99},[],{"trials":1248,"activeCount":99},[],{"trials":1250,"activeCount":99},[1251],{"nctId":1252,"briefTitle":1253,"status":1165,"phases":1254,"primaryCompletion":1255,"completion":1255,"start":1256,"enrollment":1257,"conditions":1258,"interventions":1260},"NCT03216967","Multicenter Randomized Two-arms Study Evaluating the BK Viral Clearance in Kidney Transplant Recipients With BK Viremia.",[91],"2024-08-01","2018-01-15",130,[1259],"BK Virus Nephropathy After Kidney Transplantation",[1239],{"trials":1262,"activeCount":99},[],{"intervention":1264,"totalTrials":95,"cells":1265},"L-arginine",{"EARLY_PHASE1":1266,"PHASE1":1268,"PHASE2":1270,"PHASE3":1272,"PHASE4":1274,"NA":1290},{"trials":1267,"activeCount":99},[],{"trials":1269,"activeCount":99},[],{"trials":1271,"activeCount":99},[],{"trials":1273,"activeCount":99},[],{"trials":1275,"activeCount":99},[1276],{"nctId":1277,"briefTitle":1278,"status":1165,"phases":1279,"primaryCompletion":1280,"completion":1281,"start":1282,"enrollment":1283,"conditions":1284,"interventions":1288},"NCT02117206","Protective Effects of L-arginine During Reperfusion by Femoropopliteal Bypass for Lower Limb Ischemic Syndrome in Humans",[91],"2012-03","2013-11","2005-11",60,[1285,1286,1287],"Skeletal Muscle Ischemia","Severe Lower Limb Ischemia","Mitochondrial Dysfunction",[1264,1289],"Nacl",{"trials":1291,"activeCount":99},[],{"intervention":1289,"totalTrials":95,"cells":1293},{"EARLY_PHASE1":1294,"PHASE1":1296,"PHASE2":1298,"PHASE3":1300,"PHASE4":1302,"NA":1308},{"trials":1295,"activeCount":99},[],{"trials":1297,"activeCount":99},[],{"trials":1299,"activeCount":99},[],{"trials":1301,"activeCount":99},[],{"trials":1303,"activeCount":99},[1304],{"nctId":1277,"briefTitle":1278,"status":1165,"phases":1305,"primaryCompletion":1280,"completion":1281,"start":1282,"enrollment":1283,"conditions":1306,"interventions":1307},[91],[1285,1286,1287],[1264,1289],{"trials":1309,"activeCount":99},[],{"intervention":1311,"totalTrials":95,"cells":1312},"Human serum albumin infusion 4%",{"EARLY_PHASE1":1313,"PHASE1":1315,"PHASE2":1317,"PHASE3":1319,"PHASE4":1321,"NA":1336},{"trials":1314,"activeCount":99},[],{"trials":1316,"activeCount":99},[],{"trials":1318,"activeCount":99},[],{"trials":1320,"activeCount":99},[],{"trials":1322,"activeCount":99},[1323],{"nctId":1324,"briefTitle":1325,"status":1326,"phases":1327,"primaryCompletion":1328,"completion":1328,"start":1329,"enrollment":1330,"conditions":1331,"interventions":1334},"NCT02755155","Optimization of Therapeutic Human Serum Albumin Infusion in Selected Critically Ill Patients","TERMINATED",[91],"2019-08-10","2016-09",138,[977,1332,1333],"Systemic Inflammatory Response Syndrome (SIRS)","Hypoalbuminaemia",[1311,1335],"Human serum albumin infusion 20%",{"trials":1337,"activeCount":99},[],{"intervention":1335,"totalTrials":95,"cells":1339},{"EARLY_PHASE1":1340,"PHASE1":1342,"PHASE2":1344,"PHASE3":1346,"PHASE4":1348,"NA":1354},{"trials":1341,"activeCount":99},[],{"trials":1343,"activeCount":99},[],{"trials":1345,"activeCount":99},[],{"trials":1347,"activeCount":99},[],{"trials":1349,"activeCount":99},[1350],{"nctId":1324,"briefTitle":1325,"status":1326,"phases":1351,"primaryCompletion":1328,"completion":1328,"start":1329,"enrollment":1330,"conditions":1352,"interventions":1353},[91],[977,1332,1333],[1311,1335],{"trials":1355,"activeCount":99},[],{"intervention":1357,"totalTrials":95,"cells":1358},"Heparin, IV route, based on patients body weights",{"EARLY_PHASE1":1359,"PHASE1":1361,"PHASE2":1363,"PHASE3":1365,"PHASE4":1367,"NA":1382},{"trials":1360,"activeCount":99},[],{"trials":1362,"activeCount":99},[],{"trials":1364,"activeCount":99},[],{"trials":1366,"activeCount":99},[],{"trials":1368,"activeCount":99},[1369],{"nctId":1370,"briefTitle":1371,"status":1165,"phases":1372,"primaryCompletion":1373,"completion":1374,"start":1375,"enrollment":1283,"conditions":1376,"interventions":1380},"NCT02675647","Heparin Based on Ideal Body Weight for Cardiopulmonary Bypass in Obese Patients",[91],"2016-12","2017-12","2015-12",[1377,1378,1379],"Cardiac Surgery","Cardiopulmonary Bypass","Obese Patients (BMI ≥ 30 kg\u002Fm²)",[1357,1381],"Protamin administration",{"trials":1383,"activeCount":99},[],{"intervention":1381,"totalTrials":95,"cells":1385},{"EARLY_PHASE1":1386,"PHASE1":1388,"PHASE2":1390,"PHASE3":1392,"PHASE4":1394,"NA":1400},{"trials":1387,"activeCount":99},[],{"trials":1389,"activeCount":99},[],{"trials":1391,"activeCount":99},[],{"trials":1393,"activeCount":99},[],{"trials":1395,"activeCount":99},[1396],{"nctId":1370,"briefTitle":1371,"status":1165,"phases":1397,"primaryCompletion":1373,"completion":1374,"start":1375,"enrollment":1283,"conditions":1398,"interventions":1399},[91],[1377,1378,1379],[1357,1381],{"trials":1401,"activeCount":99},[],{"intervention":1403,"totalTrials":95,"cells":1404},"No oral anticoagulation",{"EARLY_PHASE1":1405,"PHASE1":1407,"PHASE2":1409,"PHASE3":1411,"PHASE4":1413,"NA":1425},{"trials":1406,"activeCount":99},[],{"trials":1408,"activeCount":99},[],{"trials":1410,"activeCount":99},[],{"trials":1412,"activeCount":99},[],{"trials":1414,"activeCount":99},[1415],{"nctId":1416,"briefTitle":1417,"status":1326,"phases":1418,"primaryCompletion":1419,"completion":1419,"start":1420,"enrollment":1070,"conditions":1421,"interventions":1423},"NCT02886962","Oral Anticoagulation in Haemodialysis Patients",[91],"2023-12-01","2017-07-12",[1422],"Kidney Failure, Chronic",[1403,1424],"Oral anticoagulation with vitamin K antagonists",{"trials":1426,"activeCount":99},[],{"intervention":1424,"totalTrials":95,"cells":1428},{"EARLY_PHASE1":1429,"PHASE1":1431,"PHASE2":1433,"PHASE3":1435,"PHASE4":1437,"NA":1443},{"trials":1430,"activeCount":99},[],{"trials":1432,"activeCount":99},[],{"trials":1434,"activeCount":99},[],{"trials":1436,"activeCount":99},[],{"trials":1438,"activeCount":99},[1439],{"nctId":1416,"briefTitle":1417,"status":1326,"phases":1440,"primaryCompletion":1419,"completion":1419,"start":1420,"enrollment":1070,"conditions":1441,"interventions":1442},[91],[1422],[1403,1424],{"trials":1444,"activeCount":99},[],{"intervention":1446,"totalTrials":95,"cells":1447},"Intravenous immunoglobulins",{"EARLY_PHASE1":1448,"PHASE1":1450,"PHASE2":1452,"PHASE3":1454,"PHASE4":1456,"NA":1466},{"trials":1449,"activeCount":99},[],{"trials":1451,"activeCount":99},[],{"trials":1453,"activeCount":99},[],{"trials":1455,"activeCount":99},[],{"trials":1457,"activeCount":99},[1458],{"nctId":1459,"briefTitle":1460,"status":1165,"phases":1461,"primaryCompletion":64,"completion":64,"start":1462,"enrollment":1463,"conditions":1464,"interventions":1465},"NCT04222023","Intravenous Immunoglobulins for Prevention of BKV Infection in Kidney Transplant Recipients According to BKV Genotype-specific Neutralizing Antibody Titers at the Day of Transplantation.",[91],"2022-08-21",359,[925],[1446],{"trials":1467,"activeCount":99},[],{"intervention":1469,"totalTrials":95,"cells":1470},"betamethasone",{"EARLY_PHASE1":1471,"PHASE1":1473,"PHASE2":1475,"PHASE3":1477,"PHASE4":1479,"NA":1490},{"trials":1472,"activeCount":99},[],{"trials":1474,"activeCount":99},[],{"trials":1476,"activeCount":99},[],{"trials":1478,"activeCount":99},[],{"trials":1480,"activeCount":99},[1481],{"nctId":1482,"briefTitle":1483,"status":1165,"phases":1484,"primaryCompletion":1485,"completion":1281,"start":1486,"enrollment":522,"conditions":1487,"interventions":1489},"NCT00446953","Caesarean and Corticotherapy",[91],"2013-10","2007-02",[1488],"Neonatal Distress",[1469],{"trials":1491,"activeCount":99},[],{"intervention":1493,"totalTrials":95,"cells":1494},"12 g of L-arginine glutamate during 6 weeks twice a day",{"EARLY_PHASE1":1495,"PHASE1":1497,"PHASE2":1499,"PHASE3":1501,"PHASE4":1503,"NA":1515},{"trials":1496,"activeCount":99},[],{"trials":1498,"activeCount":99},[],{"trials":1500,"activeCount":99},[],{"trials":1502,"activeCount":99},[],{"trials":1504,"activeCount":99},[1505],{"nctId":1506,"briefTitle":1507,"status":1165,"phases":1508,"completion":1509,"start":1510,"enrollment":1511,"conditions":1512,"interventions":1514},"NCT00213915","L-arginine Supplementation and Exercise; L-arginine Supplementation and Renal Function",[91],"2004-12","2004-02",30,[1513],"Heart Transplantation",[1493],{"trials":1516,"activeCount":99},[],{"intervention":1518,"totalTrials":95,"cells":1519},"duloxetine",{"EARLY_PHASE1":1520,"PHASE1":1522,"PHASE2":1524,"PHASE3":1526,"PHASE4":1528,"NA":1541},{"trials":1521,"activeCount":99},[],{"trials":1523,"activeCount":99},[],{"trials":1525,"activeCount":99},[],{"trials":1527,"activeCount":99},[],{"trials":1529,"activeCount":99},[1530],{"nctId":1531,"briefTitle":1532,"status":1165,"phases":1533,"primaryCompletion":1534,"completion":1535,"start":1536,"enrollment":1537,"conditions":1538,"interventions":1540},"NCT02846701","Determination of the Antidepressant Duloxetine in Plasma to Improve the Knowledge of the Analgesic Action of Antidepressants on Chronic Neuropathic Pain",[91],"2017-06-20","2019-06-16","2016-11-17",8,[1539],"Neuropathic Pain",[1518],{"trials":1542,"activeCount":99},[],{"intervention":1544,"totalTrials":95,"cells":1545},"Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc iso-osmolar ionic iodinated contrast media",{"EARLY_PHASE1":1546,"PHASE1":1548,"PHASE2":1550,"PHASE3":1552,"PHASE4":1554,"NA":1567},{"trials":1547,"activeCount":99},[],{"trials":1549,"activeCount":99},[],{"trials":1551,"activeCount":99},[],{"trials":1553,"activeCount":99},[],{"trials":1555,"activeCount":99},[1556],{"nctId":1557,"briefTitle":1558,"status":1165,"phases":1559,"primaryCompletion":1560,"completion":1560,"start":1561,"enrollment":1562,"conditions":1563,"interventions":1565},"NCT03706157","Kinectics of Distribution of Doxorubicin-Lipiodol Emulsion in c-TACE",[91],"2019-10-09","2018-11-26",10,[1564],"Hepato Cellular Carcinoma",[1544,1566],"Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc normal saline",{"trials":1568,"activeCount":99},[],{"intervention":1566,"totalTrials":95,"cells":1570},{"EARLY_PHASE1":1571,"PHASE1":1573,"PHASE2":1575,"PHASE3":1577,"PHASE4":1579,"NA":1585},{"trials":1572,"activeCount":99},[],{"trials":1574,"activeCount":99},[],{"trials":1576,"activeCount":99},[],{"trials":1578,"activeCount":99},[],{"trials":1580,"activeCount":99},[1581],{"nctId":1557,"briefTitle":1558,"status":1165,"phases":1582,"primaryCompletion":1560,"completion":1560,"start":1561,"enrollment":1562,"conditions":1583,"interventions":1584},[91],[1564],[1544,1566],{"trials":1586,"activeCount":99},[],{"intervention":1588,"totalTrials":95,"cells":1589},"A-F-A-F",{"EARLY_PHASE1":1590,"PHASE1":1592,"PHASE2":1594,"PHASE3":1596,"PHASE4":1598,"NA":1611},{"trials":1591,"activeCount":99},[],{"trials":1593,"activeCount":99},[],{"trials":1595,"activeCount":99},[],{"trials":1597,"activeCount":99},[],{"trials":1599,"activeCount":99},[1600],{"nctId":1601,"briefTitle":1602,"status":1326,"phases":1603,"primaryCompletion":1604,"completion":1604,"start":1605,"enrollment":1606,"conditions":1607,"interventions":1609},"NCT04381429","Effect of Postprandial Insulin Administration of Faster-acting Insulin Analogue Versus Pre-prandial Administration of Acting-insulin Analogue in Cystic Fibrosis Related Diabetes",[91],"2025-01-20","2020-08-17",38,[1608],"Cystic Fibrosis-related Diabetes",[1588,1610],"F-A-F-A",{"trials":1612,"activeCount":99},[],{"intervention":1610,"totalTrials":95,"cells":1614},{"EARLY_PHASE1":1615,"PHASE1":1617,"PHASE2":1619,"PHASE3":1621,"PHASE4":1623,"NA":1629},{"trials":1616,"activeCount":99},[],{"trials":1618,"activeCount":99},[],{"trials":1620,"activeCount":99},[],{"trials":1622,"activeCount":99},[],{"trials":1624,"activeCount":99},[1625],{"nctId":1601,"briefTitle":1602,"status":1326,"phases":1626,"primaryCompletion":1604,"completion":1604,"start":1605,"enrollment":1606,"conditions":1627,"interventions":1628},[91],[1608],[1588,1610],{"trials":1630,"activeCount":99},[],{"intervention":1632,"totalTrials":95,"cells":1633},"infliximab, etanercept, adalimumab",{"EARLY_PHASE1":1634,"PHASE1":1636,"PHASE2":1638,"PHASE3":1640,"PHASE4":1642,"NA":1653},{"trials":1635,"activeCount":99},[],{"trials":1637,"activeCount":99},[],{"trials":1639,"activeCount":99},[],{"trials":1641,"activeCount":99},[],{"trials":1643,"activeCount":99},[1644],{"nctId":1645,"briefTitle":1646,"status":1165,"phases":1647,"primaryCompletion":1648,"completion":1648,"start":1649,"enrollment":1143,"conditions":1650,"interventions":1651},"NCT01000441","Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis",[91],"2013-08-12","2009-12-23",[29],[1632,1652],"abatacept, rituximab or tocilizumab",{"trials":1654,"activeCount":99},[],{"intervention":1652,"totalTrials":95,"cells":1656},{"EARLY_PHASE1":1657,"PHASE1":1659,"PHASE2":1661,"PHASE3":1663,"PHASE4":1665,"NA":1671},{"trials":1658,"activeCount":99},[],{"trials":1660,"activeCount":99},[],{"trials":1662,"activeCount":99},[],{"trials":1664,"activeCount":99},[],{"trials":1666,"activeCount":99},[1667],{"nctId":1645,"briefTitle":1646,"status":1165,"phases":1668,"primaryCompletion":1648,"completion":1648,"start":1649,"enrollment":1143,"conditions":1669,"interventions":1670},[91],[29],[1632,1652],{"trials":1672,"activeCount":99},[],{"intervention":1674,"totalTrials":95,"cells":1675},"losartan, hydrochlorothiazide",{"EARLY_PHASE1":1676,"PHASE1":1678,"PHASE2":1680,"PHASE3":1682,"PHASE4":1684,"NA":1698},{"trials":1677,"activeCount":99},[],{"trials":1679,"activeCount":99},[],{"trials":1681,"activeCount":99},[],{"trials":1683,"activeCount":99},[],{"trials":1685,"activeCount":99},[1686],{"nctId":1687,"briefTitle":1688,"status":1689,"phases":1690,"start":1691,"enrollment":296,"conditions":1692,"interventions":1696},"NCT00369538","Specific Blockage of Angiotensine 2 and Podocyturia in Glomerular Nephropathies With Hypertension and Proteinuria","SUSPENDED",[91],"2006-08",[1693,1694,1695],"Proteinuria","Hypertension","End Stage Renal Disease",[1674,1697],"hydrochlorothiazide, losartan",{"trials":1699,"activeCount":99},[],{"intervention":1697,"totalTrials":95,"cells":1701},{"EARLY_PHASE1":1702,"PHASE1":1704,"PHASE2":1706,"PHASE3":1708,"PHASE4":1710,"NA":1716},{"trials":1703,"activeCount":99},[],{"trials":1705,"activeCount":99},[],{"trials":1707,"activeCount":99},[],{"trials":1709,"activeCount":99},[],{"trials":1711,"activeCount":99},[1712],{"nctId":1687,"briefTitle":1688,"status":1689,"phases":1713,"start":1691,"enrollment":296,"conditions":1714,"interventions":1715},[91],[1693,1694,1695],[1674,1697],{"trials":1717,"activeCount":99},[],{"intervention":1719,"totalTrials":95,"cells":1720},"Pravastatin, Carvedilol, Perindopril",{"EARLY_PHASE1":1721,"PHASE1":1723,"PHASE2":1725,"PHASE3":1727,"PHASE4":1729,"NA":1739},{"trials":1722,"activeCount":99},[],{"trials":1724,"activeCount":99},[],{"trials":1726,"activeCount":99},[],{"trials":1728,"activeCount":99},[],{"trials":1730,"activeCount":99},[1731],{"nctId":1732,"briefTitle":1733,"status":1326,"phases":1734,"start":1735,"enrollment":296,"conditions":1736,"interventions":1738},"NCT00402376","Evaluation of Myocardial Improvement in Patients Supported by Ventricular Assist Device Under Optimal Pharmacological Therapy",[91],"2007-04",[1737],"Heart Failure",[1719],{"trials":1740,"activeCount":99},[],{"intervention":1742,"totalTrials":1743,"cells":1744},"URAPIDIL",2,{"EARLY_PHASE1":1745,"PHASE1":1747,"PHASE2":1749,"PHASE3":1751,"PHASE4":1776,"NA":1778},{"trials":1746,"activeCount":99},[],{"trials":1748,"activeCount":99},[],{"trials":1750,"activeCount":99},[],{"trials":1752,"activeCount":99},[1753,1764],{"nctId":1754,"briefTitle":1755,"status":1138,"phases":1756,"primaryCompletion":1757,"completion":1758,"start":1759,"enrollment":615,"conditions":1760,"interventions":1762},"NCT00409253","Treatment of Severe Hypertension During Pre-Eclampsia: A Preliminary Equivalence Study Between Urapidil and Nicardipine",[90],"2010-06","2010-08","2007-06",[1761],"Hypertension During Pre-Eclampsia",[1742,1763],"NICARDIPINE",{"nctId":1765,"briefTitle":1766,"status":1326,"phases":1767,"primaryCompletion":1768,"completion":1768,"start":1769,"enrollment":1770,"conditions":1771,"interventions":1773},"NCT02558023","The Treatment of Hypertension Associated With Severe Preeclampsia (PE). A Trial of Urapidil Versus Nicardipine",[90],"2020-08","2015-09",14,[1694,1772],"Preeclampsia",[1774,1775],"Urapidil","Nicardipine",{"trials":1777,"activeCount":99},[],{"trials":1779,"activeCount":99},[],{"intervention":1763,"totalTrials":1743,"cells":1781},{"EARLY_PHASE1":1782,"PHASE1":1784,"PHASE2":1786,"PHASE3":1788,"PHASE4":1798,"NA":1800},{"trials":1783,"activeCount":99},[],{"trials":1785,"activeCount":99},[],{"trials":1787,"activeCount":99},[],{"trials":1789,"activeCount":99},[1790,1794],{"nctId":1754,"briefTitle":1755,"status":1138,"phases":1791,"primaryCompletion":1757,"completion":1758,"start":1759,"enrollment":615,"conditions":1792,"interventions":1793},[90],[1761],[1742,1763],{"nctId":1765,"briefTitle":1766,"status":1326,"phases":1795,"primaryCompletion":1768,"completion":1768,"start":1769,"enrollment":1770,"conditions":1796,"interventions":1797},[90],[1694,1772],[1774,1775],{"trials":1799,"activeCount":99},[],{"trials":1801,"activeCount":99},[],{"intervention":1803,"totalTrials":1743,"cells":1804},"Hydroxychloroquine",{"EARLY_PHASE1":1805,"PHASE1":1807,"PHASE2":1809,"PHASE3":1811,"PHASE4":1836,"NA":1838},{"trials":1806,"activeCount":99},[],{"trials":1808,"activeCount":99},[],{"trials":1810,"activeCount":99},[],{"trials":1812,"activeCount":99},[1813,1824],{"nctId":1814,"briefTitle":1815,"status":1816,"phases":1817,"primaryCompletion":1818,"completion":1818,"start":1818,"enrollment":99,"conditions":1819,"interventions":1821},"NCT04347512","EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA","WITHDRAWN",[90],"2020-06-02",[1820],"Sars-CoV-2, Community-Acquired Pneumonia,COVID-19",[1822,1803,1823],"Hydroxychloroquine and azithromycin treatment arm.","Control arm",{"nctId":1825,"briefTitle":1826,"status":1326,"phases":1827,"primaryCompletion":1828,"completion":1829,"start":1830,"enrollment":19,"conditions":1831,"interventions":1833},"NCT04359953","Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19",[90],"2022-04-01","2022-06-01","2020-04-25",[1832],"COVID-19 Infection",[1803,1834,1835],"Azithromycin","Telmisartan",{"trials":1837,"activeCount":99},[],{"trials":1839,"activeCount":99},[],{"intervention":1841,"totalTrials":95,"cells":1842},"Cliavist",{"EARLY_PHASE1":1843,"PHASE1":1845,"PHASE2":1847,"PHASE3":1849,"PHASE4":1861,"NA":1863},{"trials":1844,"activeCount":99},[],{"trials":1846,"activeCount":99},[],{"trials":1848,"activeCount":99},[],{"trials":1850,"activeCount":99},[1851],{"nctId":1852,"briefTitle":1853,"status":1138,"phases":1854,"primaryCompletion":1855,"completion":1856,"start":1857,"enrollment":706,"conditions":1858,"interventions":1860},"NCT00372281","Cliavist in Infectious and Degenerative Diseases of the Spine",[90],"2009-08","2009-12","2007-03",[1859],"Spine Infection",[1841],{"trials":1862,"activeCount":99},[],{"trials":1864,"activeCount":99},[],{"intervention":1866,"totalTrials":95,"cells":1867},"acid tranexamic",{"EARLY_PHASE1":1868,"PHASE1":1870,"PHASE2":1872,"PHASE3":1874,"PHASE4":1886,"NA":1888},{"trials":1869,"activeCount":99},[],{"trials":1871,"activeCount":99},[],{"trials":1873,"activeCount":99},[],{"trials":1875,"activeCount":99},[1876],{"nctId":1877,"briefTitle":1878,"status":1326,"phases":1879,"primaryCompletion":1880,"completion":1281,"start":1881,"enrollment":1257,"conditions":1882,"interventions":1884},"NCT00657384","Tranexamic Acid Versus Placebo to Reduce Perioperative Bleeding After Major Hepatectomy",[90],"2013-08-20","2008-08-20",[1883],"Blood Loss, Surgical",[1866,1885],"Nacl 0.9%",{"trials":1887,"activeCount":99},[],{"trials":1889,"activeCount":99},[],{"intervention":1885,"totalTrials":95,"cells":1891},{"EARLY_PHASE1":1892,"PHASE1":1894,"PHASE2":1896,"PHASE3":1898,"PHASE4":1904,"NA":1906},{"trials":1893,"activeCount":99},[],{"trials":1895,"activeCount":99},[],{"trials":1897,"activeCount":99},[],{"trials":1899,"activeCount":99},[1900],{"nctId":1877,"briefTitle":1878,"status":1326,"phases":1901,"primaryCompletion":1880,"completion":1281,"start":1881,"enrollment":1257,"conditions":1902,"interventions":1903},[90],[1883],[1866,1885],{"trials":1905,"activeCount":99},[],{"trials":1907,"activeCount":99},[],{"intervention":1909,"totalTrials":95,"cells":1910},"Atropine 0.01%",{"EARLY_PHASE1":1911,"PHASE1":1913,"PHASE2":1915,"PHASE3":1917,"PHASE4":1930,"NA":1932},{"trials":1912,"activeCount":99},[],{"trials":1914,"activeCount":99},[],{"trials":1916,"activeCount":99},[],{"trials":1918,"activeCount":99},[1919],{"nctId":1920,"briefTitle":1921,"status":1326,"phases":1922,"primaryCompletion":1923,"completion":1924,"start":1925,"enrollment":1283,"conditions":1926,"interventions":1929},"NCT04173780","Topical 0.01% Atropine for the Control of Fast Progressing Myopia",[89,90],"2024-05-15","2024-06-03","2020-02-12",[1927,1928],"Myopia Progressing","Childhood",[1909],{"trials":1931,"activeCount":99},[],{"trials":1933,"activeCount":99},[],{"intervention":1935,"totalTrials":95,"cells":1936},"Non-surgical periodontal treatment and azithromycin treatment",{"EARLY_PHASE1":1937,"PHASE1":1939,"PHASE2":1941,"PHASE3":1943,"PHASE4":1954,"NA":1956},{"trials":1938,"activeCount":99},[],{"trials":1940,"activeCount":99},[],{"trials":1942,"activeCount":99},[],{"trials":1944,"activeCount":99},[1945],{"nctId":1946,"briefTitle":1947,"status":1326,"phases":1948,"primaryCompletion":1949,"completion":1949,"start":1950,"enrollment":30,"conditions":1951,"interventions":1953},"NCT04198649","Effect of Azithromycin on Failure Proportion of Severe Periodontitis Non-surgical Treatment",[90],"2023-11-02","2021-11-02",[1952],"Severe Chronic Periodontitis",[1935],{"trials":1955,"activeCount":99},[],{"trials":1957,"activeCount":99},[],{"intervention":1822,"totalTrials":95,"cells":1959},{"EARLY_PHASE1":1960,"PHASE1":1962,"PHASE2":1964,"PHASE3":1966,"PHASE4":1972,"NA":1974},{"trials":1961,"activeCount":99},[],{"trials":1963,"activeCount":99},[],{"trials":1965,"activeCount":99},[],{"trials":1967,"activeCount":99},[1968],{"nctId":1814,"briefTitle":1815,"status":1816,"phases":1969,"primaryCompletion":1818,"completion":1818,"start":1818,"enrollment":99,"conditions":1970,"interventions":1971},[90],[1820],[1822,1803,1823],{"trials":1973,"activeCount":99},[],{"trials":1975,"activeCount":99},[],{"intervention":1823,"totalTrials":95,"cells":1977},{"EARLY_PHASE1":1978,"PHASE1":1980,"PHASE2":1982,"PHASE3":1984,"PHASE4":1990,"NA":1992},{"trials":1979,"activeCount":99},[],{"trials":1981,"activeCount":99},[],{"trials":1983,"activeCount":99},[],{"trials":1985,"activeCount":99},[1986],{"nctId":1814,"briefTitle":1815,"status":1816,"phases":1987,"primaryCompletion":1818,"completion":1818,"start":1818,"enrollment":99,"conditions":1988,"interventions":1989},[90],[1820],[1822,1803,1823],{"trials":1991,"activeCount":99},[],{"trials":1993,"activeCount":99},[],{"intervention":1995,"totalTrials":95,"cells":1996},"Biological functionalization of the prosthetic materials by PRF",{"EARLY_PHASE1":1997,"PHASE1":1999,"PHASE2":2001,"PHASE3":2003,"PHASE4":2014,"NA":2016},{"trials":1998,"activeCount":99},[],{"trials":2000,"activeCount":99},[],{"trials":2002,"activeCount":99},[],{"trials":2004,"activeCount":99},[2005],{"nctId":2006,"briefTitle":2007,"status":1326,"phases":2008,"primaryCompletion":2009,"completion":2009,"start":2010,"enrollment":1511,"conditions":2011,"interventions":2013},"NCT03861182","Contribution of PRF in CDH in Children With Prothetic Patch Closure",[90],"2019-12-10","2019-09-12",[2012],"Congenital Diaphragmatic Hernias",[1995],{"trials":2015,"activeCount":99},[],{"trials":2017,"activeCount":99},[],{"intervention":2019,"totalTrials":95,"cells":2020},"Tocilizumab",{"EARLY_PHASE1":2021,"PHASE1":2023,"PHASE2":2025,"PHASE3":2027,"PHASE4":2039,"NA":2041},{"trials":2022,"activeCount":99},[],{"trials":2024,"activeCount":99},[],{"trials":2026,"activeCount":99},[],{"trials":2028,"activeCount":99},[2029],{"nctId":2030,"briefTitle":2031,"status":1165,"phases":2032,"primaryCompletion":2033,"completion":2033,"start":2034,"enrollment":2035,"conditions":2036,"interventions":2038},"NCT01782235","Efficacy of Tocilizumab in Primary Sjögren's Syndrome.",[89,90],"2018-07-16","2013-07-24",110,[2037],"Primary Sjögren's Syndrome (pSS)",[2019],{"trials":2040,"activeCount":99},[],{"trials":2042,"activeCount":99},[],{"intervention":2044,"totalTrials":95,"cells":2045},"filgrastim",{"EARLY_PHASE1":2046,"PHASE1":2048,"PHASE2":2050,"PHASE3":2052,"PHASE4":2063,"NA":2065},{"trials":2047,"activeCount":99},[],{"trials":2049,"activeCount":99},[],{"trials":2051,"activeCount":99},[],{"trials":2053,"activeCount":99},[2054],{"nctId":2055,"briefTitle":2056,"status":1165,"phases":2057,"completion":1691,"start":2058,"enrollment":522,"conditions":2059,"interventions":2061},"NCT00213759","Prevention Trial of Nosocomial Infections in Neutropenic Prematures With G-CSF",[90],"2002-03",[2060],"Neutropenia in Prematures",[2044,2062],"dextrose 5%",{"trials":2064,"activeCount":99},[],{"trials":2066,"activeCount":99},[],{"intervention":2062,"totalTrials":95,"cells":2068},{"EARLY_PHASE1":2069,"PHASE1":2071,"PHASE2":2073,"PHASE3":2075,"PHASE4":2081,"NA":2083},{"trials":2070,"activeCount":99},[],{"trials":2072,"activeCount":99},[],{"trials":2074,"activeCount":99},[],{"trials":2076,"activeCount":99},[2077],{"nctId":2055,"briefTitle":2056,"status":1165,"phases":2078,"completion":1691,"start":2058,"enrollment":522,"conditions":2079,"interventions":2080},[90],[2060],[2044,2062],{"trials":2082,"activeCount":99},[],{"trials":2084,"activeCount":99},[],{"intervention":2086,"totalTrials":95,"cells":2087},"Effects of lanreotide with current anti-diarrheal treatments",{"EARLY_PHASE1":2088,"PHASE1":2090,"PHASE2":2092,"PHASE3":2094,"PHASE4":2108,"NA":2110},{"trials":2089,"activeCount":99},[],{"trials":2091,"activeCount":99},[],{"trials":2093,"activeCount":99},[],{"trials":2095,"activeCount":99},[2096],{"nctId":2097,"briefTitle":2098,"status":1326,"phases":2099,"primaryCompletion":2100,"completion":2101,"start":2102,"enrollment":2103,"conditions":2104,"interventions":2106},"NCT02354768","Evaluation of Lanreotide Efficacity in High Output Stoma: a Multicentric Randomized Study",[90],"2017-12-31","2018-01-26","2015-10-22",19,[2105],"High Output Stoma",[2086,2107],"Effects of current anti-diarrheal treatments (diosmectite and loperamide) alone",{"trials":2109,"activeCount":99},[],{"trials":2111,"activeCount":99},[],{"intervention":2107,"totalTrials":95,"cells":2113},{"EARLY_PHASE1":2114,"PHASE1":2116,"PHASE2":2118,"PHASE3":2120,"PHASE4":2126,"NA":2128},{"trials":2115,"activeCount":99},[],{"trials":2117,"activeCount":99},[],{"trials":2119,"activeCount":99},[],{"trials":2121,"activeCount":99},[2122],{"nctId":2097,"briefTitle":2098,"status":1326,"phases":2123,"primaryCompletion":2100,"completion":2101,"start":2102,"enrollment":2103,"conditions":2124,"interventions":2125},[90],[2105],[2086,2107],{"trials":2127,"activeCount":99},[],{"trials":2129,"activeCount":99},[],{"intervention":2131,"totalTrials":95,"cells":2132},"Diltiazem",{"EARLY_PHASE1":2133,"PHASE1":2135,"PHASE2":2137,"PHASE3":2139,"PHASE4":2152,"NA":2154},{"trials":2134,"activeCount":99},[],{"trials":2136,"activeCount":99},[],{"trials":2138,"activeCount":99},[],{"trials":2140,"activeCount":99},[2141],{"nctId":2142,"briefTitle":2143,"status":1138,"phases":2144,"primaryCompletion":2145,"start":2146,"enrollment":365,"conditions":2147,"interventions":2149},"NCT01771978","Ischaemia-réperfusion During the Coronary Surgery With Beating Heart",[90],"2008-02","2002-06",[2148],"Ischaemia-reperfusion Injury",[2131,2150,2151],"Acetylcystein","diltiazem and acetylcystein",{"trials":2153,"activeCount":99},[],{"trials":2155,"activeCount":99},[],{"intervention":2150,"totalTrials":95,"cells":2157},{"EARLY_PHASE1":2158,"PHASE1":2160,"PHASE2":2162,"PHASE3":2164,"PHASE4":2170,"NA":2172},{"trials":2159,"activeCount":99},[],{"trials":2161,"activeCount":99},[],{"trials":2163,"activeCount":99},[],{"trials":2165,"activeCount":99},[2166],{"nctId":2142,"briefTitle":2143,"status":1138,"phases":2167,"primaryCompletion":2145,"start":2146,"enrollment":365,"conditions":2168,"interventions":2169},[90],[2148],[2131,2150,2151],{"trials":2171,"activeCount":99},[],{"trials":2173,"activeCount":99},[],{"intervention":2151,"totalTrials":95,"cells":2175},{"EARLY_PHASE1":2176,"PHASE1":2178,"PHASE2":2180,"PHASE3":2182,"PHASE4":2188,"NA":2190},{"trials":2177,"activeCount":99},[],{"trials":2179,"activeCount":99},[],{"trials":2181,"activeCount":99},[],{"trials":2183,"activeCount":99},[2184],{"nctId":2142,"briefTitle":2143,"status":1138,"phases":2185,"primaryCompletion":2145,"start":2146,"enrollment":365,"conditions":2186,"interventions":2187},[90],[2148],[2131,2150,2151],{"trials":2189,"activeCount":99},[],{"trials":2191,"activeCount":99},[],{"intervention":1834,"totalTrials":95,"cells":2193},{"EARLY_PHASE1":2194,"PHASE1":2196,"PHASE2":2198,"PHASE3":2200,"PHASE4":2206,"NA":2208},{"trials":2195,"activeCount":99},[],{"trials":2197,"activeCount":99},[],{"trials":2199,"activeCount":99},[],{"trials":2201,"activeCount":99},[2202],{"nctId":1825,"briefTitle":1826,"status":1326,"phases":2203,"primaryCompletion":1828,"completion":1829,"start":1830,"enrollment":19,"conditions":2204,"interventions":2205},[90],[1832],[1803,1834,1835],{"trials":2207,"activeCount":99},[],{"trials":2209,"activeCount":99},[],{"intervention":1835,"totalTrials":95,"cells":2211},{"EARLY_PHASE1":2212,"PHASE1":2214,"PHASE2":2216,"PHASE3":2218,"PHASE4":2224,"NA":2226},{"trials":2213,"activeCount":99},[],{"trials":2215,"activeCount":99},[],{"trials":2217,"activeCount":99},[],{"trials":2219,"activeCount":99},[2220],{"nctId":1825,"briefTitle":1826,"status":1326,"phases":2221,"primaryCompletion":1828,"completion":1829,"start":1830,"enrollment":19,"conditions":2222,"interventions":2223},[90],[1832],[1803,1834,1835],{"trials":2225,"activeCount":99},[],{"trials":2227,"activeCount":99},[],{"intervention":2229,"totalTrials":95,"cells":2230},"Droperidol 1,25 mg administration, Droperidol 0,625 mg administration, Odansetron 4 mg administration",{"EARLY_PHASE1":2231,"PHASE1":2233,"PHASE2":2235,"PHASE3":2237,"PHASE4":2247,"NA":2249},{"trials":2232,"activeCount":99},[],{"trials":2234,"activeCount":99},[],{"trials":2236,"activeCount":99},[],{"trials":2238,"activeCount":99},[2239],{"nctId":2240,"briefTitle":2241,"status":1165,"phases":2242,"primaryCompletion":2243,"completion":2243,"start":1485,"enrollment":1143,"conditions":2244,"interventions":2246},"NCT01942343","Akathisia in Post Operative Outpatients Surgery",[90],"2015-10",[2245],"Akathisia",[2229],{"trials":2248,"activeCount":99},[],{"trials":2250,"activeCount":99},[],{"intervention":2252,"totalTrials":95,"cells":2253},"Lidocaine 2%",{"EARLY_PHASE1":2254,"PHASE1":2256,"PHASE2":2258,"PHASE3":2260,"PHASE4":2273,"NA":2275},{"trials":2255,"activeCount":99},[],{"trials":2257,"activeCount":99},[],{"trials":2259,"activeCount":99},[],{"trials":2261,"activeCount":99},[2262],{"nctId":2263,"briefTitle":2264,"status":1326,"phases":2265,"primaryCompletion":2266,"completion":2266,"start":2267,"enrollment":1770,"conditions":2268,"interventions":2271},"NCT04609865","Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia",[90],"2022-03-17","2020-11-04",[2269,18,2270],"Acute Respiratory Distress Syndrome (ARDS)","Corona Virus Infection",[2252,2272],"Control",{"trials":2274,"activeCount":99},[],{"trials":2276,"activeCount":99},[],{"intervention":2272,"totalTrials":95,"cells":2278},{"EARLY_PHASE1":2279,"PHASE1":2281,"PHASE2":2283,"PHASE3":2285,"PHASE4":2291,"NA":2293},{"trials":2280,"activeCount":99},[],{"trials":2282,"activeCount":99},[],{"trials":2284,"activeCount":99},[],{"trials":2286,"activeCount":99},[2287],{"nctId":2263,"briefTitle":2264,"status":1326,"phases":2288,"primaryCompletion":2266,"completion":2266,"start":2267,"enrollment":1770,"conditions":2289,"interventions":2290},[90],[2269,18,2270],[2252,2272],{"trials":2292,"activeCount":99},[],{"trials":2294,"activeCount":99},[],{"intervention":2296,"totalTrials":95,"cells":2297},"Atorvastatin 80 mg",{"EARLY_PHASE1":2298,"PHASE1":2300,"PHASE2":2302,"PHASE3":2304,"PHASE4":2316,"NA":2318},{"trials":2299,"activeCount":99},[],{"trials":2301,"activeCount":99},[],{"trials":2303,"activeCount":99},[],{"trials":2305,"activeCount":99},[2306],{"nctId":2307,"briefTitle":2308,"status":1138,"phases":2309,"primaryCompletion":2310,"completion":2310,"start":2311,"enrollment":1283,"conditions":2312,"interventions":2315},"NCT00811330","Effects of High Dose Atorvastatin in Patients With Surgical Aortic Stenosis",[90],"2018-01","2008-12",[2313,2314],"Aortic Valve Stenosis","Ventricular Hypertrophy",[2296],{"trials":2317,"activeCount":99},[],{"trials":2319,"activeCount":99},[],{"intervention":2321,"totalTrials":95,"cells":2322},"Abciximab",{"EARLY_PHASE1":2323,"PHASE1":2325,"PHASE2":2327,"PHASE3":2329,"PHASE4":2342,"NA":2344},{"trials":2324,"activeCount":99},[],{"trials":2326,"activeCount":99},[],{"trials":2328,"activeCount":99},[],{"trials":2330,"activeCount":99},[2331],{"nctId":2332,"briefTitle":2333,"status":1138,"phases":2334,"primaryCompletion":1855,"completion":2335,"start":2336,"enrollment":2337,"conditions":2338,"interventions":2340},"NCT00638638","Myocardial Infarction With ST-Elevation",[90],"2010-01","2005-01",292,[2339],"Myocardial Infarction",[2321,2341],"Abciximab placebo",{"trials":2343,"activeCount":99},[],{"trials":2345,"activeCount":99},[],{"intervention":2341,"totalTrials":95,"cells":2347},{"EARLY_PHASE1":2348,"PHASE1":2350,"PHASE2":2352,"PHASE3":2354,"PHASE4":2360,"NA":2362},{"trials":2349,"activeCount":99},[],{"trials":2351,"activeCount":99},[],{"trials":2353,"activeCount":99},[],{"trials":2355,"activeCount":99},[2356],{"nctId":2332,"briefTitle":2333,"status":1138,"phases":2357,"primaryCompletion":1855,"completion":2335,"start":2336,"enrollment":2337,"conditions":2358,"interventions":2359},[90],[2339],[2321,2341],{"trials":2361,"activeCount":99},[],{"trials":2363,"activeCount":99},[],{"intervention":2365,"totalTrials":95,"cells":2366},"Treatment",{"EARLY_PHASE1":2367,"PHASE1":2369,"PHASE2":2371,"PHASE3":2373,"PHASE4":2383,"NA":2385},{"trials":2368,"activeCount":99},[],{"trials":2370,"activeCount":99},[],{"trials":2372,"activeCount":99},[],{"trials":2374,"activeCount":99},[2375],{"nctId":2376,"briefTitle":2377,"status":1138,"phases":2378,"primaryCompletion":2379,"completion":521,"start":2379,"enrollment":1283,"conditions":2380,"interventions":2382},"NCT05196503","Efficacy of an Intraoperative Periradicular Application of Platelet Rich Fibrin (PRF) on the Intensity of Residual Post-surgical Neuropathic Pain After a Surgery for Disc Herniation",[90],"2022-02-23",[1539,2381],"Chronic Postsurgical Pain",[2365],{"trials":2384,"activeCount":99},[],{"trials":2386,"activeCount":99},[],{"intervention":2388,"totalTrials":95,"cells":2389},"Privigen® 100mg\u002Fml at the dose of 2g\u002Fkg of body weight",{"EARLY_PHASE1":2390,"PHASE1":2392,"PHASE2":2394,"PHASE3":2396,"PHASE4":2409,"NA":2411},{"trials":2391,"activeCount":99},[],{"trials":2393,"activeCount":99},[],{"trials":2395,"activeCount":99},[],{"trials":2397,"activeCount":99},[2398],{"nctId":2399,"briefTitle":2400,"status":1165,"phases":2401,"primaryCompletion":2402,"completion":2402,"start":2403,"enrollment":2404,"conditions":2405,"interventions":2407},"NCT03700138","Intravenous Immunoglobulins for the Treatment of Primary Sjögren's Syndrome Associated Painful Sensory Neuropathies",[90],"2025-04-10","2019-06-19",24,[2406],"Primary Sjögren's Syndrome Painful Sensory Neuropathies",[2388,2408],"NaCl 0,9%",{"trials":2410,"activeCount":99},[],{"trials":2412,"activeCount":99},[],{"intervention":2408,"totalTrials":95,"cells":2414},{"EARLY_PHASE1":2415,"PHASE1":2417,"PHASE2":2419,"PHASE3":2421,"PHASE4":2427,"NA":2429},{"trials":2416,"activeCount":99},[],{"trials":2418,"activeCount":99},[],{"trials":2420,"activeCount":99},[],{"trials":2422,"activeCount":99},[2423],{"nctId":2399,"briefTitle":2400,"status":1165,"phases":2424,"primaryCompletion":2402,"completion":2402,"start":2403,"enrollment":2404,"conditions":2425,"interventions":2426},[90],[2406],[2388,2408],{"trials":2428,"activeCount":99},[],{"trials":2430,"activeCount":99},[],{"intervention":2432,"totalTrials":95,"cells":2433},"morphine gel",{"EARLY_PHASE1":2434,"PHASE1":2436,"PHASE2":2438,"PHASE3":2440,"PHASE4":2451,"NA":2453},{"trials":2435,"activeCount":99},[],{"trials":2437,"activeCount":99},[],{"trials":2439,"activeCount":99},[],{"trials":2441,"activeCount":99},[2442],{"nctId":2443,"briefTitle":2444,"status":1326,"phases":2445,"primaryCompletion":2446,"completion":2446,"start":1168,"enrollment":2447,"conditions":2448,"interventions":2450},"NCT02173756","Evaluation of Oral Morphine Gel in Oral Mucositis Induced by Chemotherapy in Children and Young Adults",[90],"2017-09",25,[2449],"Cancer",[2432],{"trials":2452,"activeCount":99},[],{"trials":2454,"activeCount":99},[],{"intervention":2456,"totalTrials":95,"cells":2457},"EllaOne",{"EARLY_PHASE1":2458,"PHASE1":2460,"PHASE2":2462,"PHASE3":2476,"PHASE4":2478,"NA":2480},{"trials":2459,"activeCount":99},[],{"trials":2461,"activeCount":99},[],{"trials":2463,"activeCount":99},[2464],{"nctId":2465,"briefTitle":2466,"status":1326,"phases":2467,"primaryCompletion":2468,"completion":2469,"start":2470,"enrollment":2471,"conditions":2472,"interventions":2474},"NCT02600286","Ulipristal Acetate In Disease Charcot-Marie-Tooth Type of 1A",[89],"2017-11","2017-11-02","2015-10-23",23,[2473],"CMT1A",[2456,2475],"EllaOne placebo",{"trials":2477,"activeCount":99},[],{"trials":2479,"activeCount":99},[],{"trials":2481,"activeCount":99},[],{"intervention":2475,"totalTrials":95,"cells":2483},{"EARLY_PHASE1":2484,"PHASE1":2486,"PHASE2":2488,"PHASE3":2494,"PHASE4":2496,"NA":2498},{"trials":2485,"activeCount":99},[],{"trials":2487,"activeCount":99},[],{"trials":2489,"activeCount":99},[2490],{"nctId":2465,"briefTitle":2466,"status":1326,"phases":2491,"primaryCompletion":2468,"completion":2469,"start":2470,"enrollment":2471,"conditions":2492,"interventions":2493},[89],[2473],[2456,2475],{"trials":2495,"activeCount":99},[],{"trials":2497,"activeCount":99},[],{"trials":2499,"activeCount":99},[],{"intervention":2501,"totalTrials":95,"cells":2502},"Botulinum toxin A",{"EARLY_PHASE1":2503,"PHASE1":2505,"PHASE2":2507,"PHASE3":2519,"PHASE4":2521,"NA":2523},{"trials":2504,"activeCount":99},[],{"trials":2506,"activeCount":99},[],{"trials":2508,"activeCount":99},[2509],{"nctId":2510,"briefTitle":2511,"status":1138,"phases":2512,"primaryCompletion":2513,"completion":2514,"start":2515,"enrollment":1070,"conditions":2516,"interventions":2518},"NCT02832713","Trial Comparing Botulin Toxin Versus Hyaluronic Acid by Intra-articular Injection for the Treatment of Painful Knee Osteoarthritis",[89],"2021-10","2021-12","2017-06-09",[2517],"Painful Unilateral Femorotibial Knee Osteoarthritis of Any Etiology",[2501],{"trials":2520,"activeCount":99},[],{"trials":2522,"activeCount":99},[],{"trials":2524,"activeCount":99},[],{"intervention":2526,"totalTrials":95,"cells":2527},"busulfan",{"EARLY_PHASE1":2528,"PHASE1":2530,"PHASE2":2532,"PHASE3":2545,"PHASE4":2547,"NA":2549},{"trials":2529,"activeCount":99},[],{"trials":2531,"activeCount":99},[],{"trials":2533,"activeCount":99},[2534],{"nctId":2535,"briefTitle":2536,"status":1138,"phases":2537,"primaryCompletion":2538,"completion":2539,"start":2540,"enrollment":2541,"conditions":2542,"interventions":2544},"NCT00328029","Respiratory Side Effects of Busulfan High Dose Chemotherapy in a Pediatric Population",[89],"2012-01","2012-06","2006-07",35,[2543],"Signs and Symptoms, Respiratory",[2526],{"trials":2546,"activeCount":99},[],{"trials":2548,"activeCount":99},[],{"trials":2550,"activeCount":99},[],{"intervention":2552,"totalTrials":95,"cells":2553},"Metformin",{"EARLY_PHASE1":2554,"PHASE1":2556,"PHASE2":2558,"PHASE3":2572,"PHASE4":2574,"NA":2576},{"trials":2555,"activeCount":99},[],{"trials":2557,"activeCount":99},[],{"trials":2559,"activeCount":99},[2560],{"nctId":2561,"briefTitle":2562,"status":1326,"phases":2563,"primaryCompletion":2564,"completion":2565,"start":2539,"enrollment":2566,"conditions":2567,"interventions":2570},"NCT01756105","Efficacy of Metformin in Achieving Glycaemia Goals as Recommended for the Treatment of Gestational Diabetes in Non Obese Women",[89],"2018-02","2018-06",84,[2568,2552,2365,2569],"Gestational Diabetes","Oxidative Stress",[2552,2571],"Rapid acting analog insulin Intermediate acting NPH Insulin",{"trials":2573,"activeCount":99},[],{"trials":2575,"activeCount":99},[],{"trials":2577,"activeCount":99},[],{"intervention":2571,"totalTrials":95,"cells":2579},{"EARLY_PHASE1":2580,"PHASE1":2582,"PHASE2":2584,"PHASE3":2590,"PHASE4":2592,"NA":2594},{"trials":2581,"activeCount":99},[],{"trials":2583,"activeCount":99},[],{"trials":2585,"activeCount":99},[2586],{"nctId":2561,"briefTitle":2562,"status":1326,"phases":2587,"primaryCompletion":2564,"completion":2565,"start":2539,"enrollment":2566,"conditions":2588,"interventions":2589},[89],[2568,2552,2365,2569],[2552,2571],{"trials":2591,"activeCount":99},[],{"trials":2593,"activeCount":99},[],{"trials":2595,"activeCount":99},[],{"intervention":2597,"totalTrials":95,"cells":2598},"Terbutaline sustained release 5 mg",{"EARLY_PHASE1":2599,"PHASE1":2601,"PHASE2":2603,"PHASE3":2613,"PHASE4":2615,"NA":2617},{"trials":2600,"activeCount":99},[],{"trials":2602,"activeCount":99},[],{"trials":2604,"activeCount":99},[2605],{"nctId":2606,"briefTitle":2607,"status":1326,"phases":2608,"primaryCompletion":2446,"completion":2446,"start":2538,"enrollment":296,"conditions":2609,"interventions":2612},"NCT01582646","Analgesic Effect of Beta 2-mimetics in the Treatment of Neuropathic Pain",[89],[2610,2611],"Postthoracotomy Pain","Postthoracoscopy Neuropathic Pain",[2597],{"trials":2614,"activeCount":99},[],{"trials":2616,"activeCount":99},[],{"trials":2618,"activeCount":99},[],{"intervention":2620,"totalTrials":95,"cells":2621},"Nivolumab 10 MG\u002FML Intravenous Solution [OPDIVO]",{"EARLY_PHASE1":2622,"PHASE1":2624,"PHASE2":2626,"PHASE3":2639,"PHASE4":2641,"NA":2643},{"trials":2623,"activeCount":99},[],{"trials":2625,"activeCount":99},[],{"trials":2627,"activeCount":99},[2628],{"nctId":2629,"briefTitle":2630,"status":1165,"phases":2631,"primaryCompletion":2632,"completion":2633,"start":2634,"enrollment":2103,"conditions":2635,"interventions":2637},"NCT03949153","Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis",[88,89],"2021-10-20","2022-03-18","2019-08-16",[2636],"Melanoma (Skin)",[2620,2638],"Ipilimumab",{"trials":2640,"activeCount":99},[],{"trials":2642,"activeCount":99},[],{"trials":2644,"activeCount":99},[],{"intervention":2638,"totalTrials":95,"cells":2646},{"EARLY_PHASE1":2647,"PHASE1":2649,"PHASE2":2651,"PHASE3":2657,"PHASE4":2659,"NA":2661},{"trials":2648,"activeCount":99},[],{"trials":2650,"activeCount":99},[],{"trials":2652,"activeCount":99},[2653],{"nctId":2629,"briefTitle":2630,"status":1165,"phases":2654,"primaryCompletion":2632,"completion":2633,"start":2634,"enrollment":2103,"conditions":2655,"interventions":2656},[88,89],[2636],[2620,2638],{"trials":2658,"activeCount":99},[],{"trials":2660,"activeCount":99},[],{"trials":2662,"activeCount":99},[],{"intervention":2664,"totalTrials":95,"cells":2665},"Active drug: pimavanserin 17mg",{"EARLY_PHASE1":2666,"PHASE1":2668,"PHASE2":2670,"PHASE3":2683,"PHASE4":2685,"NA":2687},{"trials":2667,"activeCount":99},[],{"trials":2669,"activeCount":99},[],{"trials":2671,"activeCount":99},[2672],{"nctId":2673,"briefTitle":2674,"status":1165,"phases":2675,"primaryCompletion":2676,"completion":2677,"start":2678,"enrollment":2679,"conditions":2680,"interventions":2682},"NCT03947216","Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.",[89],"2024-04-23","2024-06-17","2020-10-23",117,[2681],"Parkinson Disease",[2664],{"trials":2684,"activeCount":99},[],{"trials":2686,"activeCount":99},[],{"trials":2688,"activeCount":99},[],{"intervention":2690,"totalTrials":95,"cells":2691},"1- Erlotinib",{"EARLY_PHASE1":2692,"PHASE1":2694,"PHASE2":2696,"PHASE3":2708,"PHASE4":2710,"NA":2712},{"trials":2693,"activeCount":99},[],{"trials":2695,"activeCount":99},[],{"trials":2697,"activeCount":99},[2698],{"nctId":2699,"briefTitle":2700,"status":1138,"phases":2701,"primaryCompletion":2702,"completion":2702,"start":2703,"enrollment":22,"conditions":2704,"interventions":2707},"NCT01835938","Clinical Investigation of Erlotinib as an HCV Entry Inhibitor",[88,89],"2015-05","2013-05",[2705,2706],"Chronic Hepatitis C Infection","HCV Genotype 1b",[2690],{"trials":2709,"activeCount":99},[],{"trials":2711,"activeCount":99},[],{"trials":2713,"activeCount":99},[],{"intervention":2715,"totalTrials":95,"cells":2716},"Combined administration of irinotecan and rapamycin",{"EARLY_PHASE1":2717,"PHASE1":2719,"PHASE2":2731,"PHASE3":2733,"PHASE4":2735,"NA":2737},{"trials":2718,"activeCount":99},[],{"trials":2720,"activeCount":99},[2721],{"nctId":2722,"briefTitle":2723,"status":1165,"phases":2724,"primaryCompletion":2725,"completion":2725,"start":2726,"enrollment":2727,"conditions":2728,"interventions":2730},"NCT01282697","Clinical Trial of Rapamycin and Irinotecan in Pediatric Patients With Refractory Solid Tumors",[88],"2013-02-20","2011-04-22",42,[2729],"Refractory Solid Tumors in Children",[2715],{"trials":2732,"activeCount":99},[],{"trials":2734,"activeCount":99},[],{"trials":2736,"activeCount":99},[],{"trials":2738,"activeCount":99},[],{"intervention":2740,"totalTrials":2741,"cells":2742},"Blood samples",4,{"EARLY_PHASE1":2743,"PHASE1":2745,"PHASE2":2747,"PHASE3":2749,"PHASE4":2751,"NA":2763},{"trials":2744,"activeCount":99},[],{"trials":2746,"activeCount":99},[],{"trials":2748,"activeCount":99},[],{"trials":2750,"activeCount":99},[],{"trials":2752,"activeCount":99},[2753],{"nctId":2754,"briefTitle":2755,"status":1138,"phases":2756,"primaryCompletion":2757,"completion":2757,"start":2758,"enrollment":2759,"conditions":2760,"interventions":2762},"NCT02370979","Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Naïve and Experienced Patients",[91],"2017-07","2015-02",202,[2761],"HIV-1 Infection",[2740],{"trials":2764,"activeCount":99},[2765,2772,2781],{"nctId":2766,"briefTitle":2767,"status":1138,"phases":2768,"primaryCompletion":2446,"completion":1374,"start":1329,"enrollment":1511,"conditions":2769,"interventions":2771},"NCT02881333","Various Type of Genetic Events in Patients With Intellectual Disability",[],[2770],"Intellectual Disability",[2740],{"nctId":2773,"briefTitle":2774,"status":1326,"phases":2775,"completion":2776,"start":2777,"enrollment":1562,"conditions":2778,"interventions":2780},"NCT00314691","Development of New Prenatal Diagnostic Tests From Maternal Blood",[92],"2006-09","2006-04",[2779],"Hereditary Diseases",[2740],{"nctId":2782,"briefTitle":2783,"status":1165,"phases":2784,"primaryCompletion":2785,"completion":2785,"start":2786,"enrollment":2787,"conditions":2788,"interventions":2791},"NCT02400684","ENDmetriosis and Reserve Ovarienne",[],"2019-03","2015-06",118,[2789,2790],"Deep Endometriosis Stage III","Deep Endometriosis Stage IV",[2792],"blood samples",{"intervention":2794,"totalTrials":2795,"cells":2796},"Ropivacaine",3,{"EARLY_PHASE1":2797,"PHASE1":2799,"PHASE2":2801,"PHASE3":2803,"PHASE4":2815,"NA":2828},{"trials":2798,"activeCount":99},[],{"trials":2800,"activeCount":99},[],{"trials":2802,"activeCount":99},[],{"trials":2804,"activeCount":99},[2805],{"nctId":2806,"briefTitle":2807,"status":1165,"phases":2808,"primaryCompletion":2809,"completion":2810,"start":2811,"enrollment":1283,"conditions":2812,"interventions":2813},"NCT00620490","Paravertebral Analgesia Associated With Intravenous Morphine PCA After Thoracotomy",[90],"2009-02","2009-03","2008-03",[1214],[2814],"ropivacaine",{"trials":2816,"activeCount":99},[2817],{"nctId":2818,"briefTitle":2819,"status":1326,"phases":2820,"primaryCompletion":2821,"completion":2822,"start":2823,"enrollment":2824,"conditions":2825,"interventions":2827},"NCT02006355","Continuous Local Anesthesia Versus Continuous Femoral Nerve Bloc After Total Knee Arthroplasty: Impact on Mean Discharge Aptitude Delay",[91],"2016-04","2017-08-12","2014-04",36,[2826],"Total Knee Arthroplasty",[2794],{"trials":2829,"activeCount":99},[2830],{"nctId":2831,"briefTitle":2832,"status":1138,"phases":2833,"primaryCompletion":2834,"completion":2835,"start":2834,"enrollment":1257,"conditions":2836,"interventions":2841},"NCT03867695","SERRATHOR TRIAL : Interest of the Novel Serratus Plane Block in Post Operative Analgesia After Video-Assisted Thoracoscopic Lobectomy",[92],"2019-07","2020-07",[2837,2838,2839,2840],"Video Assisted Thoracoscopic Surgery","Lobectomy","Pain Post Operative","Regional Anesthesia",[2794,2842],"sterile saline",{"intervention":2844,"totalTrials":1743,"cells":2845},"blood sampling",{"EARLY_PHASE1":2846,"PHASE1":2848,"PHASE2":2850,"PHASE3":2852,"PHASE4":2854,"NA":2856},{"trials":2847,"activeCount":99},[],{"trials":2849,"activeCount":99},[],{"trials":2851,"activeCount":99},[],{"trials":2853,"activeCount":99},[],{"trials":2855,"activeCount":99},[],{"trials":2857,"activeCount":99},[2858,2869],{"nctId":2859,"briefTitle":2860,"status":1138,"phases":2861,"primaryCompletion":2862,"completion":2862,"start":1769,"enrollment":2863,"conditions":2864,"interventions":2868},"NCT02558478","Identification of New Genes Implicated in Rare Neurosensory Diseases by Whole Exome Sequencing",[],"2018-09",39,[2865,2866,2867],"Neurosensory Diseases","Retinopathy","Hearing Loss",[2844],{"nctId":2870,"briefTitle":2871,"status":1165,"phases":2872,"primaryCompletion":2702,"completion":2702,"start":2873,"enrollment":2874,"conditions":2875,"interventions":2877},"NCT01358461","Validation of a Non Invasive Blood Marker of SIDS and Vagal Disorders",[],"2011-03",240,[2876],"Vagal Syncope",[2878],"Blood sampling",{"intervention":2880,"totalTrials":95,"cells":2881},"CGH-array and exome sequencing",{"EARLY_PHASE1":2882,"PHASE1":2884,"PHASE2":2886,"PHASE3":2888,"PHASE4":2890,"NA":2892},{"trials":2883,"activeCount":99},[],{"trials":2885,"activeCount":99},[],{"trials":2887,"activeCount":99},[],{"trials":2889,"activeCount":99},[],{"trials":2891,"activeCount":99},[],{"trials":2893,"activeCount":99},[2894],{"nctId":2895,"briefTitle":2896,"status":1138,"phases":2897,"primaryCompletion":2898,"completion":2899,"start":2900,"enrollment":2901,"conditions":2902,"interventions":2906},"NCT04406480","Realization of Sequencing of All Known Human Genes in Case of Detection of Cerebral, Renal or Ophthalmological Fetal Malformations During Pregnancy in Order to Make an Etiological Diagnosis and to Precise the Fetal Prognosis",[92],"2021-09","2023-09","2020-08-05",90,[2903,2904,2905],"Fetal Malformation","Pregnancy Related","Rare Genetic Disease",[2880],{"intervention":2908,"totalTrials":95,"cells":2909},"antiretrovirals",{"EARLY_PHASE1":2910,"PHASE1":2912,"PHASE2":2914,"PHASE3":2916,"PHASE4":2918,"NA":2920},{"trials":2911,"activeCount":99},[],{"trials":2913,"activeCount":99},[],{"trials":2915,"activeCount":99},[],{"trials":2917,"activeCount":99},[],{"trials":2919,"activeCount":99},[],{"trials":2921,"activeCount":99},[2922],{"nctId":2923,"briefTitle":2924,"status":1326,"phases":2925,"primaryCompletion":2926,"completion":2927,"start":2926,"enrollment":11,"conditions":2928,"interventions":2931},"NCT00146094","Bone Mineral Density (BMD) in HIV Infection",[92],"2003-03","2006-12-14",[2929,2930],"Osteopenia","Osteoporosis",[2908],{"intervention":2933,"totalTrials":95,"cells":2934},"seropositive for Toxoplasma gondii",{"EARLY_PHASE1":2935,"PHASE1":2937,"PHASE2":2939,"PHASE3":2941,"PHASE4":2943,"NA":2945},{"trials":2936,"activeCount":99},[],{"trials":2938,"activeCount":99},[],{"trials":2940,"activeCount":99},[],{"trials":2942,"activeCount":99},[],{"trials":2944,"activeCount":99},[],{"trials":2946,"activeCount":99},[2947],{"nctId":2948,"briefTitle":2949,"status":1326,"phases":2950,"primaryCompletion":2951,"completion":2951,"start":2952,"enrollment":19,"conditions":2953,"interventions":2957},"NCT02863588","Determination of Genetic Susceptibility in Severe Recurrences of Ocular Toxoplasmosis",[92],"2019-11-11","2017-03-30",[2954,2955,2956],"Toxoplasmosis Infection","Genotype II","Ocular Toxoplasmosis With Recurrences",[2933],{"intervention":2959,"totalTrials":95,"cells":2960},"RNA sequencing",{"EARLY_PHASE1":2961,"PHASE1":2963,"PHASE2":2965,"PHASE3":2967,"PHASE4":2969,"NA":2971},{"trials":2962,"activeCount":99},[],{"trials":2964,"activeCount":99},[],{"trials":2966,"activeCount":99},[],{"trials":2968,"activeCount":99},[],{"trials":2970,"activeCount":99},[],{"trials":2972,"activeCount":99},[2973],{"nctId":2974,"briefTitle":2975,"status":1138,"phases":2976,"primaryCompletion":2834,"completion":2977,"start":2978,"enrollment":2979,"conditions":2980,"interventions":2983},"NCT03971292","Interest of High-throughput Sequencing of RNAs for the Diagnosis of Heterogeneous Genetic Diseases",[],"2022-07","2019-06",15,[2981,2982],"DNA Sequencing","Diagnosis of Genetic Diseases of Heterogeneous Origin",[2959],{"intervention":2985,"totalTrials":95,"cells":2986},"Lumacaftor-Ivacaftor treatment",{"EARLY_PHASE1":2987,"PHASE1":2989,"PHASE2":2991,"PHASE3":2993,"PHASE4":2995,"NA":2997},{"trials":2988,"activeCount":99},[],{"trials":2990,"activeCount":99},[],{"trials":2992,"activeCount":99},[],{"trials":2994,"activeCount":99},[],{"trials":2996,"activeCount":99},[],{"trials":2998,"activeCount":99},[2999],{"nctId":3000,"briefTitle":3001,"status":1165,"phases":3002,"primaryCompletion":3003,"completion":3003,"start":3004,"enrollment":3005,"conditions":3006,"interventions":3009},"NCT03512119","Observational Study of Glucose Tolerance Abnormalities in Patient With Cystic Fibrosis Homozygous for Phe 508 Del CFTR Treated by Lumacaftor-Ivacaftor",[],"2019-04-10","2016-02-11",55,[3007,3008],"Cystic Fibrosis Homozygous for Phe 508 Del CFTR","Glucose Intolerance or Newly Diagnosis Diabetes",[2985],{"intervention":3011,"totalTrials":95,"cells":3012},"Focal epilepsy of unknown cause",{"EARLY_PHASE1":3013,"PHASE1":3015,"PHASE2":3017,"PHASE3":3019,"PHASE4":3021,"NA":3023},{"trials":3014,"activeCount":99},[],{"trials":3016,"activeCount":99},[],{"trials":3018,"activeCount":99},[],{"trials":3020,"activeCount":99},[],{"trials":3022,"activeCount":99},[],{"trials":3024,"activeCount":99},[3025],{"nctId":3026,"briefTitle":3027,"status":1138,"phases":3028,"primaryCompletion":2757,"completion":2757,"start":2786,"enrollment":522,"conditions":3029,"interventions":3031},"NCT02885207","Interest Balance Auto-immune Population in Patients With Focal Epilepsy of Unknown Cause, Not Structural, Not Genetics, Newly Diagnosed",[92],[3030],"Epilepsy",[3011],{"intervention":3033,"totalTrials":95,"cells":3034},"Cytokines dosage in Aqueous humor",{"EARLY_PHASE1":3035,"PHASE1":3037,"PHASE2":3039,"PHASE3":3041,"PHASE4":3043,"NA":3045},{"trials":3036,"activeCount":99},[],{"trials":3038,"activeCount":99},[],{"trials":3040,"activeCount":99},[],{"trials":3042,"activeCount":99},[],{"trials":3044,"activeCount":99},[],{"trials":3046,"activeCount":99},[3047],{"nctId":3048,"briefTitle":3049,"status":1165,"phases":3050,"primaryCompletion":3051,"completion":3051,"start":3052,"enrollment":3053,"conditions":3054,"interventions":3056},"NCT02818062","Severe Intraocular Infection",[],"2011-09","2008-01",263,[3055],"Endophthalmitis",[3033],{"intervention":3058,"totalTrials":95,"cells":3059},"Prednisolone",{"EARLY_PHASE1":3060,"PHASE1":3062,"PHASE2":3064,"PHASE3":3066,"PHASE4":3068,"NA":3070},{"trials":3061,"activeCount":99},[],{"trials":3063,"activeCount":99},[],{"trials":3065,"activeCount":99},[],{"trials":3067,"activeCount":99},[],{"trials":3069,"activeCount":99},[],{"trials":3071,"activeCount":99},[3072],{"nctId":3073,"briefTitle":3074,"status":1816,"phases":3075,"primaryCompletion":3076,"completion":3077,"start":3078,"enrollment":99,"conditions":3079,"interventions":3081},"NCT05300490","Prednisolone Urinary Excretion Kinetics",[],"2023-11","2024-01-01","2023-05",[3080],"Articular Cartilage Disorder of Knee",[3058],{"intervention":3083,"totalTrials":95,"cells":3084},"genome analyzes",{"EARLY_PHASE1":3085,"PHASE1":3087,"PHASE2":3089,"PHASE3":3091,"PHASE4":3093,"NA":3095},{"trials":3086,"activeCount":99},[],{"trials":3088,"activeCount":99},[],{"trials":3090,"activeCount":99},[],{"trials":3092,"activeCount":99},[],{"trials":3094,"activeCount":99},[],{"trials":3096,"activeCount":99},[3097],{"nctId":3098,"briefTitle":3099,"status":1138,"phases":3100,"conditions":3101,"interventions":3102},"NCT00851331","Genetic Basis of Idiopathic Focal Epilepsies With Cognitif Deficits",[92],[3030],[3083],{"intervention":3104,"totalTrials":95,"cells":3105},"karyotype",{"EARLY_PHASE1":3106,"PHASE1":3108,"PHASE2":3110,"PHASE3":3112,"PHASE4":3114,"NA":3116},{"trials":3107,"activeCount":99},[],{"trials":3109,"activeCount":99},[],{"trials":3111,"activeCount":99},[],{"trials":3113,"activeCount":99},[],{"trials":3115,"activeCount":99},[],{"trials":3117,"activeCount":99},[3118],{"nctId":3119,"briefTitle":3120,"status":1138,"phases":3121,"primaryCompletion":3122,"completion":3122,"start":3123,"enrollment":591,"conditions":3124,"interventions":3126},"NCT01663675","Trisomy 21 in Adulthood",[],"2019-10","2014-11",[3125],"Down Syndrome",[3104],{"intervention":3128,"totalTrials":95,"cells":3129},"Nitrous Oxide inhalation",{"EARLY_PHASE1":3130,"PHASE1":3132,"PHASE2":3134,"PHASE3":3136,"PHASE4":3138,"NA":3140},{"trials":3131,"activeCount":99},[],{"trials":3133,"activeCount":99},[],{"trials":3135,"activeCount":99},[],{"trials":3137,"activeCount":99},[],{"trials":3139,"activeCount":99},[],{"trials":3141,"activeCount":99},[3142],{"nctId":3143,"briefTitle":3144,"status":1138,"phases":3145,"primaryCompletion":3146,"completion":3147,"start":3146,"enrollment":1511,"conditions":3148,"interventions":3150},"NCT05167331","Comparative Clinical Study Between Virtual Reality Hypnosis and Nitrous Oxide Inhalation for Dental Anxie",[92],"2022-02","2023-03",[3149],"Dental Anxiety",[3128],{"intervention":3152,"totalTrials":95,"cells":3153},"group of patients",{"EARLY_PHASE1":3154,"PHASE1":3156,"PHASE2":3158,"PHASE3":3160,"PHASE4":3162,"NA":3164},{"trials":3155,"activeCount":99},[],{"trials":3157,"activeCount":99},[],{"trials":3159,"activeCount":99},[],{"trials":3161,"activeCount":99},[],{"trials":3163,"activeCount":99},[],{"trials":3165,"activeCount":99},[3166],{"nctId":3167,"briefTitle":3168,"status":1138,"phases":3169,"primaryCompletion":1373,"completion":1373,"start":1168,"enrollment":1070,"conditions":3170,"interventions":3172},"NCT02904850","Validation of a Kinetic Model of Erlotinib",[],[3171],"Lung Cancer",[3152],{"intervention":3174,"totalTrials":95,"cells":3175},"Additional blood sampling",{"EARLY_PHASE1":3176,"PHASE1":3178,"PHASE2":3180,"PHASE3":3182,"PHASE4":3184,"NA":3186},{"trials":3177,"activeCount":99},[],{"trials":3179,"activeCount":99},[],{"trials":3181,"activeCount":99},[],{"trials":3183,"activeCount":99},[],{"trials":3185,"activeCount":99},[],{"trials":3187,"activeCount":99},[3188],{"nctId":3189,"briefTitle":3190,"status":1138,"phases":3191,"primaryCompletion":3192,"completion":3192,"start":3193,"enrollment":1070,"conditions":3194,"interventions":3196},"NCT05099458","T-cell Dysfunction in Chronic HBV Infection",[92],"2022-04-25","2019-04-15",[3195],"Chronic Hepatitis B Virus",[3174],{"intervention":3198,"totalTrials":95,"cells":3199},"Blood collection",{"EARLY_PHASE1":3200,"PHASE1":3202,"PHASE2":3204,"PHASE3":3206,"PHASE4":3208,"NA":3210},{"trials":3201,"activeCount":99},[],{"trials":3203,"activeCount":99},[],{"trials":3205,"activeCount":99},[],{"trials":3207,"activeCount":99},[],{"trials":3209,"activeCount":99},[],{"trials":3211,"activeCount":99},[3212],{"nctId":3213,"briefTitle":3214,"status":1326,"phases":3215,"primaryCompletion":3216,"completion":3217,"start":3218,"enrollment":3219,"conditions":3220,"interventions":3223},"NCT05419986","Epigenetic Biomarker for Opioid Use Disorder",[92],"2022-09-15","2023-02-07","2022-06-23",11,[3221,3222],"Opioid Use Disorder","Addiction",[3198],{"intervention":2842,"totalTrials":95,"cells":3225},{"EARLY_PHASE1":3226,"PHASE1":3228,"PHASE2":3230,"PHASE3":3232,"PHASE4":3234,"NA":3236},{"trials":3227,"activeCount":99},[],{"trials":3229,"activeCount":99},[],{"trials":3231,"activeCount":99},[],{"trials":3233,"activeCount":99},[],{"trials":3235,"activeCount":99},[],{"trials":3237,"activeCount":99},[3238],{"nctId":2831,"briefTitle":2832,"status":1138,"phases":3239,"primaryCompletion":2834,"completion":2835,"start":2834,"enrollment":1257,"conditions":3240,"interventions":3241},[92],[2837,2838,2839,2840],[2794,2842],{"intervention":3243,"totalTrials":95,"cells":3244},"Systemic analgesia + Continuous regional anesthesia",{"EARLY_PHASE1":3245,"PHASE1":3247,"PHASE2":3249,"PHASE3":3251,"PHASE4":3253,"NA":3255},{"trials":3246,"activeCount":99},[],{"trials":3248,"activeCount":99},[],{"trials":3250,"activeCount":99},[],{"trials":3252,"activeCount":99},[],{"trials":3254,"activeCount":99},[],{"trials":3256,"activeCount":99},[3257],{"nctId":3258,"briefTitle":3259,"status":1138,"phases":3260,"primaryCompletion":3261,"completion":3261,"start":1485,"enrollment":222,"conditions":3262,"interventions":3265},"NCT01947660","Continuous Regional Anesthesia for Septic Limb Orthopedic Surgery",[92],"2015-11",[3263,3264],"Osteo Arthritis","Cellulitis",[3243,3266],"Systemic analgesia",{"intervention":3266,"totalTrials":95,"cells":3268},{"EARLY_PHASE1":3269,"PHASE1":3271,"PHASE2":3273,"PHASE3":3275,"PHASE4":3277,"NA":3279},{"trials":3270,"activeCount":99},[],{"trials":3272,"activeCount":99},[],{"trials":3274,"activeCount":99},[],{"trials":3276,"activeCount":99},[],{"trials":3278,"activeCount":99},[],{"trials":3280,"activeCount":99},[3281],{"nctId":3258,"briefTitle":3259,"status":1138,"phases":3282,"primaryCompletion":3261,"completion":3261,"start":1485,"enrollment":222,"conditions":3283,"interventions":3284},[92],[3263,3264],[3243,3266],{"intervention":3286,"totalTrials":95,"cells":3287},"Methylene blue",{"EARLY_PHASE1":3288,"PHASE1":3290,"PHASE2":3292,"PHASE3":3294,"PHASE4":3296,"NA":3298},{"trials":3289,"activeCount":99},[],{"trials":3291,"activeCount":99},[],{"trials":3293,"activeCount":99},[],{"trials":3295,"activeCount":99},[],{"trials":3297,"activeCount":99},[],{"trials":3299,"activeCount":99},[3300],{"nctId":3301,"briefTitle":3302,"status":1165,"phases":3303,"primaryCompletion":1735,"start":2777,"enrollment":321,"conditions":3304,"interventions":3306},"NCT00314405","Identification of Sentinel Lymph Nodes With Methylene Blue and Isotope",[92],[3305],"Infiltrative Breast Cancer",[3286,3307],"Rhenium sulfure",{"intervention":3307,"totalTrials":95,"cells":3309},{"EARLY_PHASE1":3310,"PHASE1":3312,"PHASE2":3314,"PHASE3":3316,"PHASE4":3318,"NA":3320},{"trials":3311,"activeCount":99},[],{"trials":3313,"activeCount":99},[],{"trials":3315,"activeCount":99},[],{"trials":3317,"activeCount":99},[],{"trials":3319,"activeCount":99},[],{"trials":3321,"activeCount":99},[3322],{"nctId":3301,"briefTitle":3302,"status":1165,"phases":3323,"primaryCompletion":1735,"start":2777,"enrollment":321,"conditions":3324,"interventions":3325},[92],[3305],[3286,3307],{"intervention":3327,"totalTrials":95,"cells":3328},"Genetic blood sample",{"EARLY_PHASE1":3329,"PHASE1":3331,"PHASE2":3333,"PHASE3":3335,"PHASE4":3337,"NA":3339},{"trials":3330,"activeCount":99},[],{"trials":3332,"activeCount":99},[],{"trials":3334,"activeCount":99},[],{"trials":3336,"activeCount":99},[],{"trials":3338,"activeCount":99},[],{"trials":3340,"activeCount":99},[3341],{"nctId":3342,"briefTitle":3343,"status":1165,"phases":3344,"primaryCompletion":3345,"completion":3345,"start":3346,"enrollment":3347,"conditions":3348,"interventions":3353},"NCT02026895","Virulence of Staphylococcus Lugdunensis in Severe Infections",[92],"2016-02","2013-12",82,[3349,3350,3351,3352],"Staphylococcus Lugdunensis","Bacteremia","Endocarditis","Virulence Factors",[3327],{"intervention":3355,"totalTrials":95,"cells":3356},"FACS analyses",{"EARLY_PHASE1":3357,"PHASE1":3359,"PHASE2":3361,"PHASE3":3363,"PHASE4":3365,"NA":3367},{"trials":3358,"activeCount":99},[],{"trials":3360,"activeCount":99},[],{"trials":3362,"activeCount":99},[],{"trials":3364,"activeCount":99},[],{"trials":3366,"activeCount":99},[],{"trials":3368,"activeCount":99},[3369],{"nctId":3370,"briefTitle":3371,"status":1165,"phases":3372,"primaryCompletion":3373,"completion":3374,"start":3373,"enrollment":3375,"conditions":3376,"interventions":3378},"NCT03427593","Severe PID With Lymphoproliferation and Neutropenia",[92],"2018-03-13","2019-12-05",27,[3377],"Primary Immune-Deficiency (PID) Common Variable Immune Deficiency (CVID)",[3355,3379,3380],"Target Sequencing by NGS","Whole Exome Sequencing",{"intervention":3379,"totalTrials":95,"cells":3382},{"EARLY_PHASE1":3383,"PHASE1":3385,"PHASE2":3387,"PHASE3":3389,"PHASE4":3391,"NA":3393},{"trials":3384,"activeCount":99},[],{"trials":3386,"activeCount":99},[],{"trials":3388,"activeCount":99},[],{"trials":3390,"activeCount":99},[],{"trials":3392,"activeCount":99},[],{"trials":3394,"activeCount":99},[3395],{"nctId":3370,"briefTitle":3371,"status":1165,"phases":3396,"primaryCompletion":3373,"completion":3374,"start":3373,"enrollment":3375,"conditions":3397,"interventions":3398},[92],[3377],[3355,3379,3380],{"intervention":3380,"totalTrials":95,"cells":3400},{"EARLY_PHASE1":3401,"PHASE1":3403,"PHASE2":3405,"PHASE3":3407,"PHASE4":3409,"NA":3411},{"trials":3402,"activeCount":99},[],{"trials":3404,"activeCount":99},[],{"trials":3406,"activeCount":99},[],{"trials":3408,"activeCount":99},[],{"trials":3410,"activeCount":99},[],{"trials":3412,"activeCount":99},[3413],{"nctId":3370,"briefTitle":3371,"status":1165,"phases":3414,"primaryCompletion":3373,"completion":3374,"start":3373,"enrollment":3375,"conditions":3415,"interventions":3416},[92],[3377],[3355,3379,3380],{"intervention":3418,"totalTrials":95,"cells":3419},"Salivary and blood sampling, as part of routine care. Collection of exfoliated teeth.",{"EARLY_PHASE1":3420,"PHASE1":3422,"PHASE2":3424,"PHASE3":3426,"PHASE4":3428,"NA":3430},{"trials":3421,"activeCount":99},[],{"trials":3423,"activeCount":99},[],{"trials":3425,"activeCount":99},[],{"trials":3427,"activeCount":99},[],{"trials":3429,"activeCount":99},[],{"trials":3431,"activeCount":99},[3432],{"nctId":3433,"briefTitle":3434,"status":1326,"phases":3435,"primaryCompletion":3436,"completion":3437,"start":3438,"enrollment":3439,"conditions":3440,"interventions":3441},"NCT01746121","Amelogenesis Imperfecta",[],"2013-03","2016-01","2009-11",600,[3434],[3418],{"intervention":3443,"totalTrials":95,"cells":3444},"injection of HES \" Voluven® \"",{"EARLY_PHASE1":3445,"PHASE1":3447,"PHASE2":3449,"PHASE3":3451,"PHASE4":3453,"NA":3455},{"trials":3446,"activeCount":99},[],{"trials":3448,"activeCount":99},[],{"trials":3450,"activeCount":99},[],{"trials":3452,"activeCount":99},[],{"trials":3454,"activeCount":99},[],{"trials":3456,"activeCount":99},[3457],{"nctId":3458,"briefTitle":3459,"status":1165,"phases":3460,"primaryCompletion":3461,"completion":3461,"start":3462,"enrollment":296,"conditions":3463,"interventions":3465},"NCT02570724","HES Patch Versus Blood Patch",[92],"2018-08","2013-06",[3464],"Intracranial Hypotension",[3443,3466],"blood patch",{"intervention":3466,"totalTrials":95,"cells":3468},{"EARLY_PHASE1":3469,"PHASE1":3471,"PHASE2":3473,"PHASE3":3475,"PHASE4":3477,"NA":3479},{"trials":3470,"activeCount":99},[],{"trials":3472,"activeCount":99},[],{"trials":3474,"activeCount":99},[],{"trials":3476,"activeCount":99},[],{"trials":3478,"activeCount":99},[],{"trials":3480,"activeCount":99},[3481],{"nctId":3458,"briefTitle":3459,"status":1165,"phases":3482,"primaryCompletion":3461,"completion":3461,"start":3462,"enrollment":296,"conditions":3483,"interventions":3484},[92],[3464],[3443,3466],{"intervention":3486,"totalTrials":95,"cells":3487},"Diazepam",{"EARLY_PHASE1":3488,"PHASE1":3490,"PHASE2":3492,"PHASE3":3494,"PHASE4":3496,"NA":3498},{"trials":3489,"activeCount":99},[],{"trials":3491,"activeCount":99},[],{"trials":3493,"activeCount":99},[],{"trials":3495,"activeCount":99},[],{"trials":3497,"activeCount":99},[],{"trials":3499,"activeCount":99},[3500],{"nctId":3501,"briefTitle":3502,"status":1165,"phases":3503,"primaryCompletion":2311,"completion":2311,"start":3504,"enrollment":3505,"conditions":3506,"interventions":3508},"NCT00696033","Exploring the Effects of Diazepam and Lorazepam",[92],"2007-07",22,[3507],"Healthy Subjects",[3486,3509],"Lorazepam",{"intervention":3509,"totalTrials":95,"cells":3511},{"EARLY_PHASE1":3512,"PHASE1":3514,"PHASE2":3516,"PHASE3":3518,"PHASE4":3520,"NA":3522},{"trials":3513,"activeCount":99},[],{"trials":3515,"activeCount":99},[],{"trials":3517,"activeCount":99},[],{"trials":3519,"activeCount":99},[],{"trials":3521,"activeCount":99},[],{"trials":3523,"activeCount":99},[3524],{"nctId":3501,"briefTitle":3502,"status":1165,"phases":3525,"primaryCompletion":2311,"completion":2311,"start":3504,"enrollment":3505,"conditions":3526,"interventions":3527},[92],[3507],[3486,3509],{"intervention":3529,"totalTrials":95,"cells":3530},"OctaplasLG®",{"EARLY_PHASE1":3531,"PHASE1":3533,"PHASE2":3535,"PHASE3":3537,"PHASE4":3539,"NA":3541},{"trials":3532,"activeCount":99},[],{"trials":3534,"activeCount":99},[],{"trials":3536,"activeCount":99},[],{"trials":3538,"activeCount":99},[],{"trials":3540,"activeCount":99},[],{"trials":3542,"activeCount":99},[3543],{"nctId":3544,"briefTitle":3545,"status":1165,"phases":3546,"primaryCompletion":3547,"completion":3548,"start":3549,"enrollment":1283,"conditions":3550,"interventions":3551},"NCT04580563","Study Assessing Efficacy of Plasmatherapy in Septic Shock-induced Coagulopathy: Feasibility Study",[92],"2022-12-09","2023-01-03","2020-10-22",[455,732,899],[3529,3552],"0.9% NaCl",{"intervention":3552,"totalTrials":95,"cells":3554},{"EARLY_PHASE1":3555,"PHASE1":3557,"PHASE2":3559,"PHASE3":3561,"PHASE4":3563,"NA":3565},{"trials":3556,"activeCount":99},[],{"trials":3558,"activeCount":99},[],{"trials":3560,"activeCount":99},[],{"trials":3562,"activeCount":99},[],{"trials":3564,"activeCount":99},[],{"trials":3566,"activeCount":99},[3567],{"nctId":3544,"briefTitle":3545,"status":1165,"phases":3568,"primaryCompletion":3547,"completion":3548,"start":3549,"enrollment":1283,"conditions":3569,"interventions":3570},[92],[455,732,899],[3529,3552],{"intervention":3572,"totalTrials":95,"cells":3573},"SRAS-CoV-2 vaccination immunological response",{"EARLY_PHASE1":3574,"PHASE1":3576,"PHASE2":3578,"PHASE3":3580,"PHASE4":3582,"NA":3584},{"trials":3575,"activeCount":99},[],{"trials":3577,"activeCount":99},[],{"trials":3579,"activeCount":99},[],{"trials":3581,"activeCount":99},[],{"trials":3583,"activeCount":99},[],{"trials":3585,"activeCount":99},[3586],{"nctId":3587,"briefTitle":3588,"status":1326,"phases":3589,"primaryCompletion":3590,"completion":3591,"start":3590,"enrollment":25,"conditions":3592,"interventions":3594},"NCT04894253","Immune Response to SARS-CoV-2 Vaccination in Systemic Lupus",[],"2021-06-07","2023-12-22",[3593],"Systemic Lupus",[3572],{"intervention":3596,"totalTrials":95,"cells":3597},"elexacaftor-tezacaftor-ivacaftor treatment",{"EARLY_PHASE1":3598,"PHASE1":3600,"PHASE2":3602,"PHASE3":3604,"PHASE4":3606,"NA":3608},{"trials":3599,"activeCount":99},[],{"trials":3601,"activeCount":99},[],{"trials":3603,"activeCount":99},[],{"trials":3605,"activeCount":99},[],{"trials":3607,"activeCount":99},[],{"trials":3609,"activeCount":99},[3610],{"nctId":3611,"briefTitle":3612,"status":1165,"phases":3613,"primaryCompletion":3614,"completion":3615,"start":3616,"enrollment":3617,"conditions":3618,"interventions":3619},"NCT06331000","Effect of One Year Elexacaftor-tezacaftor-ivacaftor Treatment",[],"2025-02-20","2025-02-24","2024-04-08",184,[32],[3596],{"intervention":3621,"totalTrials":95,"cells":3622},"Myocardium biopsy",{"EARLY_PHASE1":3623,"PHASE1":3625,"PHASE2":3627,"PHASE3":3629,"PHASE4":3631,"NA":3633},{"trials":3624,"activeCount":99},[],{"trials":3626,"activeCount":99},[],{"trials":3628,"activeCount":99},[],{"trials":3630,"activeCount":99},[],{"trials":3632,"activeCount":99},[],{"trials":3634,"activeCount":99},[3635],{"nctId":3636,"briefTitle":3637,"status":1816,"phases":3638,"primaryCompletion":3639,"completion":3639,"start":922,"enrollment":99,"conditions":3640,"interventions":3641},"NCT05830760","Expression of Sodium-glucose Co-transporter 2 in Human Heart",[92],"2025-10",[2313],[3621],{"intervention":3643,"totalTrials":95,"cells":3644},"Blood sample for specific analyzes",{"EARLY_PHASE1":3645,"PHASE1":3647,"PHASE2":3649,"PHASE3":3651,"PHASE4":3653,"NA":3655},{"trials":3646,"activeCount":99},[],{"trials":3648,"activeCount":99},[],{"trials":3650,"activeCount":99},[],{"trials":3652,"activeCount":99},[],{"trials":3654,"activeCount":99},[],{"trials":3656,"activeCount":99},[3657],{"nctId":3658,"briefTitle":3659,"status":1138,"phases":3660,"primaryCompletion":3661,"completion":3662,"start":3663,"enrollment":1511,"conditions":3664,"interventions":3666},"NCT03278977","Apparent Life Threatening Events, Sudden Infant Death Syndrome and Muscarinic Receptors",[92],"2022-12","2023-12","2018-09-15",[3665],"Apparent Life-Threatening Event in Infants Under One Year of Age",[3643],{"intervention":3668,"totalTrials":95,"cells":3669},"a blood sample",{"EARLY_PHASE1":3670,"PHASE1":3672,"PHASE2":3674,"PHASE3":3676,"PHASE4":3678,"NA":3680},{"trials":3671,"activeCount":99},[],{"trials":3673,"activeCount":99},[],{"trials":3675,"activeCount":99},[],{"trials":3677,"activeCount":99},[],{"trials":3679,"activeCount":99},[],{"trials":3681,"activeCount":99},[3682],{"nctId":3683,"briefTitle":3684,"status":1138,"phases":3685,"primaryCompletion":3686,"completion":3686,"start":3687,"enrollment":3688,"conditions":3689,"interventions":3691},"NCT02288663","Renal Function Assessment in the Elderly Using Plasma Creatinine Assay and Lean Body Mass Measurement",[92],"2022-11-02","2014-11-03",220,[3690],"Renal Function",[3668,3692,3693],"albumin or blood in urine","51Cr-EDTA plasma clearance",{"intervention":3692,"totalTrials":95,"cells":3695},{"EARLY_PHASE1":3696,"PHASE1":3698,"PHASE2":3700,"PHASE3":3702,"PHASE4":3704,"NA":3706},{"trials":3697,"activeCount":99},[],{"trials":3699,"activeCount":99},[],{"trials":3701,"activeCount":99},[],{"trials":3703,"activeCount":99},[],{"trials":3705,"activeCount":99},[],{"trials":3707,"activeCount":99},[3708],{"nctId":3683,"briefTitle":3684,"status":1138,"phases":3709,"primaryCompletion":3686,"completion":3686,"start":3687,"enrollment":3688,"conditions":3710,"interventions":3711},[92],[3690],[3668,3692,3693],{"intervention":3693,"totalTrials":95,"cells":3713},{"EARLY_PHASE1":3714,"PHASE1":3716,"PHASE2":3718,"PHASE3":3720,"PHASE4":3722,"NA":3724},{"trials":3715,"activeCount":99},[],{"trials":3717,"activeCount":99},[],{"trials":3719,"activeCount":99},[],{"trials":3721,"activeCount":99},[],{"trials":3723,"activeCount":99},[],{"trials":3725,"activeCount":99},[3726],{"nctId":3683,"briefTitle":3684,"status":1138,"phases":3727,"primaryCompletion":3686,"completion":3686,"start":3687,"enrollment":3688,"conditions":3728,"interventions":3729},[92],[3690],[3668,3692,3693],{"intervention":3731,"totalTrials":95,"cells":3732},"Telomerase activity on a blood sample",{"EARLY_PHASE1":3733,"PHASE1":3735,"PHASE2":3737,"PHASE3":3739,"PHASE4":3741,"NA":3743},{"trials":3734,"activeCount":99},[],{"trials":3736,"activeCount":99},[],{"trials":3738,"activeCount":99},[],{"trials":3740,"activeCount":99},[],{"trials":3742,"activeCount":99},[],{"trials":3744,"activeCount":99},[3745],{"nctId":3746,"briefTitle":3747,"status":1165,"phases":3748,"primaryCompletion":3749,"completion":3750,"start":3749,"enrollment":321,"conditions":3751,"interventions":3752},"NCT02900326","Mindfulness-based Stress Reduction (MBSR) Program Combined With Endurance Exercise Training: a Help in Treatment for Breast Cancer",[92],"2015-05-12","2021-03-30",[27],[3731],{"intervention":3754,"totalTrials":95,"cells":3755},"Implementation of a pulp medication in compliance with the dental emergency management protocol: articaïne",{"EARLY_PHASE1":3756,"PHASE1":3758,"PHASE2":3760,"PHASE3":3762,"PHASE4":3764,"NA":3766},{"trials":3757,"activeCount":99},[],{"trials":3759,"activeCount":99},[],{"trials":3761,"activeCount":99},[],{"trials":3763,"activeCount":99},[],{"trials":3765,"activeCount":99},[],{"trials":3767,"activeCount":99},[3768],{"nctId":3769,"briefTitle":3770,"status":1165,"phases":3771,"primaryCompletion":3772,"completion":3773,"start":3772,"enrollment":321,"conditions":3774,"interventions":3779},"NCT03472456","Endodontic Medications for Irreversible Pulpitis: Articaine or Eugenol?",[],"2018-03-22","2019-10-24",[3775,3776,3777,3778],"Pulpitides","Endodontic Inflammation","Toothaches","Operative Dentistry",[3754,3780],"Implementation of a pulp medication in compliance with the dental emergency management protocol: eugenol",{"intervention":3780,"totalTrials":95,"cells":3782},{"EARLY_PHASE1":3783,"PHASE1":3785,"PHASE2":3787,"PHASE3":3789,"PHASE4":3791,"NA":3793},{"trials":3784,"activeCount":99},[],{"trials":3786,"activeCount":99},[],{"trials":3788,"activeCount":99},[],{"trials":3790,"activeCount":99},[],{"trials":3792,"activeCount":99},[],{"trials":3794,"activeCount":99},[3795],{"nctId":3769,"briefTitle":3770,"status":1165,"phases":3796,"primaryCompletion":3772,"completion":3773,"start":3772,"enrollment":321,"conditions":3797,"interventions":3798},[],[3775,3776,3777,3778],[3754,3780]]